

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 229 121 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

07.08.2002 Bulletin 2002/32

(51) Int Cl.⁷: **C12N 15/52, C12N 9/00,**

C12P 13/14, C12N 1/21

// C12R1/15

(21) Application number: **02001993.1**

(22) Date of filing: **05.02.2002**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **05.02.2001 JP 2001028163**

30.05.2001 JP 2001162806

(71) Applicant: **Ajinomoto Co., Inc.**

Tokyo 104 (JP)

(72) Inventors:

- **Nakamura, Jun, c/o Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)

- **Izui, Hiroshi, c/o Ajinomoto Co., Inc.**

Kawasaki-shi, Kanagawa (JP)

- **Moriguchi, Kayo, c/o Ajinomoto Co., Inc.**

Kawasaki-shi, Kanagawa (JP)

- **Kawashima, Hiroki, Ajinomoto Co., Inc.**

Kawasaki-shi, Kanagawa (JP)

- **Nakamatsu, Tsuyoshi,**

c/o Tokyo Denki University

Tokyo (JP)

- **Kurahashi, Osamu, c/o Ajinomoto Co., Inc.**

Kawasaki-shi, Kanagawa (JP)

(74) Representative: **HOFFMANN - EITLE**

Patent- und Rechtsanwälte

Arabellastrasse 4

81925 München (DE)

(54) **Method for producing L-glutamine by fermentation and L-glutamine producing bacterium**

(57) L-Glutamine is produced by culturing a coryneform bacterium which has L-glutamine producing ability and has been modified so that its intracellular glutamine synthetase activity should be enhanced, preferably which has been further modified so that its intracellular

glutamate dehydrogenase activity should be enhanced, in a medium to produce and accumulate L-glutamine in the medium and collecting the L-glutamine.

EP 1 229 121 A2

Description**BACKGROUND OF THE INVENTION**5 **Field of the Invention**

[0001] The present invention relates to an L-glutamine producing bacterium belonging to coryneform bacteria and a method for producing L-glutamine. L-Glutamine is an industrially useful amino acid as an ingredient of seasonings, liver function promoting agents, amino acid transfusions, comprehensive amino acid preparations and so forth.

10

Related Art

[0002] In order to produce L-amino acids by fermentation, methods for improving microorganisms by breeding have been used abundantly. That is, since production ability of wild strains per se for L-amino acid production is extremely low in many cases, there have been known methods of imparting auxotrophy or analogue resistance by mutation or imparting mutation for metabolic regulation and methods utilizing a combination of these. Although L-glutamine can be obtained with an appropriate yield by the aforementioned methods, it is indispensable to further improve the fermentation yield in order to industrially produce L-glutamine at a low cost.

15

[0003] Further, the L-glutamine fermentation also suffers from the problem of by-production of L-glutamic acid. A method for solving this problem is proposed in, for example, Japanese Patent Laid-open Publication (Kokai) No. 3-232497. Although the production of L-glutamic acid can be suppressed to a certain extent by this method, there is still by-production of L-glutamic acid and the yield of L-glutamine is insufficient.

20

[0004] Since such improvements of L-glutamine producing bacteria as mentioned above utilize methods of treating a host bacterium with a mutagenizing agent or the like and selecting a strain showing improved productivity for L-glutamine from bacteria randomly incorporated with mutations, they require much labor and suffer from difficulties.

25

SUMMARY OF THE INVENTION

[0005] An object of the present invention is to find characteristics of coryneform bacteria providing improvement of L-glutamine productivity and suppression of by-production of L-glutamic acid, and thereby provide a method for producing L-glutamine utilizing a strain having such characteristics.

30

[0006] The inventors of the present invention assiduously studied in order to achieve the aforementioned object. As a result, they found that a strain of coryneform bacterium of which intracellular glutamine synthetase activity was enhanced showed more excellent L-glutamine producing ability and could markedly suppress the by-production of L-glutamic acid compared with strains showing the glutamine synthetase activity comparable to that of wild strains. Further, they found that production rate of L-glutamine was improved by simultaneously enhancing glutamine synthetase activity and glutamate dehydrogenase activity. Furthermore, they successfully isolated a novel gene coding for glutamine synthetase and a novel gene coding for glutamine synthetase adenylyl transferase, and thus accomplished the present invention.

35

[0007] That is, the present invention provides the followings.

40

(1) A coryneform bacterium which has L-glutamine producing ability and has been modified so that its intracellular glutamine synthetase activity should be enhanced.

45

(2) The bacterium according to (1), wherein the glutamine synthetase activity is enhanced by increasing expression amount of a glutamine synthetase gene.

(3) The bacterium according to (2), wherein the expression amount of the glutamine synthetase gene is increased by increasing copy number of a gene coding for glutamine synthetase or modifying an expression control sequence of the gene so that expression of the gene coding for the intracellular glutamine synthetase of the bacterium should be enhanced.

50

(4) The bacterium according to (1), wherein the glutamine synthetase activity is enhanced by deficiency in activity control of intracellular glutamine synthetase by adenylylation.

(5) The bacterium according to (4), wherein the activity control of intracellular glutamine synthetase by adenylylation is defected by one or more of harboring glutamine synthetase of which activity control by adenylylation is defected, decrease of glutamine synthetase adenylyl transferase activities in the bacterial cell and decrease of PII protein activity in the bacterial cell.

55

(6) The bacterium according to any one of (1) to (5), wherein the bacterium has been further modified so that its intracellular glutamate dehydrogenase activity should be enhanced.

(7) The bacterium according to (6), wherein the glutamate dehydrogenase activity is enhanced by increasing ex-

pression amount of a glutamate dehydrogenase gene.

(8) The bacterium according to (7), wherein the expression amount of the glutamate dehydrogenase gene is increased by increasing copy number of the gene coding for glutamate dehydrogenase or modifying an expression control sequence of the gene so that expression of the gene coding for the intracellular glutamate dehydrogenase of the bacterium should be increased.

(9) A method for producing L-glutamine, which comprises culturing a bacterium according to any one of (1) to (8) in a medium to produce and accumulate L-glutamine in the medium and collecting the L-glutamine.

(10) A DNA coding for a protein defined in the following (A) or (B):

(A) a protein that has the amino acid sequence of SEQ ID NO: 2,

(B) a protein that has the amino acid sequence of SEQ ID NO: 2 including substitution, deletion, insertion, addition or inversion of one or several amino acid residues and has glutamine synthetase activity.

(11) The DNA according to (10), which is a DNA defined in the following (a) or (b):

(a) a DNA containing the nucleotide sequence of the nucleotide numbers 659-1996 in the nucleotide sequence of SEQ ID NO: 1,

(b) a DNA that is hybridizable with the nucleotide sequence of the nucleotide numbers 659-1996 in the nucleotide sequence of SEQ ID NO: 1 or a probe that can be prepared from the sequence under the stringent conditions and codes for a protein having glutamine synthetase activity.

(12) A DNA coding for a protein defined in the following (C) or (D):

(C) a protein that has the amino acid sequence of SEQ ID NO: 3,

(D) a protein that has the amino acid sequence of SEQ ID NO: 3 including substitution, deletion, insertion, addition or inversion of one or several amino acid residues and has glutamine synthetase adenylyl transferase activities.

(13) The DNA according to (12), which is a DNA defined in the following (c) or (d):

(c) a DNA containing the nucleotide sequence of nucleotide numbers 2006-5200 in the nucleotide sequence of SEQ ID NO: 1,

(d) a DNA that is hybridizable with the nucleotide sequence of the nucleotide numbers 2006-5200 in the nucleotide sequence of SEQ ID NO: 1 or a probe that can be prepared from the sequence under the stringent conditions and codes for a protein having glutamine synthetase adenylyl transferase activities.

[0008] According to the present invention, the by-production of L-glutamic acid can be suppressed and the production efficiency of L-glutamine can be improved in the production of L-glutamine by fermentation utilizing coryneform bacteria. Further, the DNA of the present invention can be used for breeding of L-glutamine producing coryneform bacteria.

PREFERRED EMBODIMENTS OF THE INVENTION

[0009] Hereafter, the present invention will be explained in detail.

(1) Coryneform bacteria of the present invention

[0010] In the present invention, "coryneform bacteria" include those having hitherto been classified into the genus *Brevibacterium*, but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform bacteria are mentioned below.

Corynebacterium acetoacidophilum

Corynebacterium acetoglutamicum

Corynebacterium alkanolyticum

Corynebacterium callunae

Corynebacterium glutamicum

Corynebacterium lilium

Corynebacterium melassecola

Corynebacterium thermoaminogenes

Corynebacterium herculis
Brevibacterium divaricatum
Brevibacterium flavum
Brevibacterium immariophilum
5 *Brevibacterium lactofermentum*
Brevibacterium roseum
Brevibacterium saccharolyticum
Brevibacterium thiogenitalis
Brevibacterium ammoniagenes
10 *Brevibacterium album*
Brevibacterium cerium
Microbacterium ammoniaphilum

[0011] Specifically, the following strains can be exemplified.

15 *Corynebacterium acetoacidophilum* ATCC 13870
Corynebacterium acetoglutamicum ATCC 15806
Corynebacterium alkanolyticum ATCC 21511
Corynebacterium callunae ATCC 15991
Corynebacterium glutamicum ATCC 13020, 13032, 13060
Corynebacterium lilium ATCC 15990
20 *Corynebacterium melassecola* ATCC 17965
Corynebacterium thermoaminogenes AJ12340 (FERM BP-1539)
Corynebacterium herculis ATCC 13868
Brevibacterium divaricatum ATCC 14020
Brevibacterium flavum ATCC 13826, ATCC 14067, AJ12418 (FERM BP-2205)
25 *Brevibacterium immariophilum* ATCC 14068
Brevibacterium lactofermentum ATCC 13869
Brevibacterium roseum ATCC 13825
Brevibacterium saccharolyticum ATCC 14066
Brevibacterium thiogenitalis ATCC 19240
30 *Brevibacterium ammoniagenes* ATCC 6871, ATCC 6872
Brevibacterium album ATCC 15111
Brevibacterium cerium ATCC 15112
Microbacterium ammoniaphilum ATCC 15354

35 [0012] To obtain these strains, one can be provided them from, for example, the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209, United States of America). That is, each strain is assigned its registration number, and one can request provision of each strain by utilizing its registration number. The registration numbers corresponding to the strains are indicated on the catalog of the American Type Culture Collection. Further, the AJ12340 strain was deposited on October 27, 1987 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, the independent administrative corporation, National Institute of Advanced Industrial Science and Technology, International Patent Or-
40 ganism Depository (Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, postal code: 305-8566)) as an international deposit under the provisions of the Budapest Treaty, and received an accession number of FERM BP-1539. The AJ12418 strain was deposited on January 5, 1989 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry as an international
45 deposit under the provisions of the Budapest Treaty and received an accession number of FERM BP-2205.

[0013] In the present invention, "L-glutamine producing ability" means an ability to accumulate L-glutamine in a medium, when the coryneform bacterium of the present invention is cultured in the medium. This L-glutamine producing ability may be possessed by the bacterium as a property of a wild strain of coryneform bacteria or may be imparted or enhanced by breeding.

50 [0014] For imparting or enhancing the L-glutamine producing ability by breeding, there can be used the method of isolation of 6-diazo-5-oxo-norleucine resistant strain (Japanese Patent Laid-open Publication No. 3-232497), the method of isolation of purine analogue resistant and/or methionine sulfoxide resistant strain (Japanese Patent Laid-open Publication No. 61-202694), the method of isolation of α -ketomalonic acid resistant strain (Japanese Patent Laid-open Publication No. 56-151495), the method of imparting resistance to a peptide containing glutamic acid (Japanese Patent Laid-open Publication No. 2-186994) and so forth. As specific examples of coryneform bacteria having L-glutamine
55 producing ability, the following strains can be mentioned.

Brevibacterium flavum AJ11573 (FERM P-5492, refer to Japanese Patent Laid-open Publication No. 56-151495) *Brevibacterium flavum* AJ12210 (FERM P-8123, refer to Japanese Patent Laid-open Publication No. 61-202694) *Brevibac-*

terium flavum AJ12212 (FERM P-8123, refer to Japanese Patent Laid-open Publication No. 61-202694) *Brevibacterium flavum* AJ12418 (FERM-BP2205, refer to Japanese Patent Laid-open Publication No. 2-186994) *Brevibacterium flavum* DH18 (FERM P-11116, refer to Japanese Patent Laid-open Publication No. 3-232497) *Corynebacterium melassecola* DH344 (FERM P-11117, refer to Japanese Patent Laid-open Publication No. 3-232497) *Corynebacterium glutamicum* AJ11574 (FERM P-5493, refer to Japanese Patent Laid-open Publication No. No. 56-151495)

[0015] The term "modified so that intracellular glutamine synthetase (henceforth also referred to as "GS") activity should be enhanced" means that the GS activity per cell has become higher than that of a non-modified strain, for example, a wild-type coryneform bacterium. For example, there can be mentioned a case where number of GS molecules per cell increases, a case where GS specific activity per GS molecule increases and so forth. Further, as a wild-type coryneform bacterium that serves as an object for comparison, for example, the *Brevibacterium flavum* ATCC 14067 can be mentioned. As a result of enhancement of intracellular GS activity, there are obtained an effect that the amount of L-glutamine accumulation in a medium increases, an effect that the by-production of L-glutamic acid decreases and so forth.

[0016] Enhancement of GS activity in a coryneform bacterium cell can be attained by enhancement of expression of a gene coding for GS. Increase of the expression amount of the gene can be attained by increasing copy number of the gene coding for GS. For example, a recombinant DNA can be prepared by ligating a gene fragment coding for GS with a vector functioning in the bacterium, preferably a multi-copy type vector, and introduced into a host having L-glutamine producing ability to transform it. Alternatively, the aforementioned recombinant DNA can be introduced into a wild-type coryneform bacterium to obtain a transformant, and then the transformant can be imparted with L-glutamine producing ability.

[0017] As the GS gene, any of genes derived from coryneform bacteria and genes derived from other organisms such as bacteria belonging to the genus *Escherichia* can be used. Among these, genes derived from coryneform bacteria are preferred in view of ease of expression.

[0018] As the gene coding for GS of coryneform bacteria, *glnA* has already been elucidated (*FEMS Microbiology Letters*, 81-88, 154, 1997). Therefore, a GS gene can be obtained by PCR (polymerase chain reaction; refer to White, T.J. *et al.*, *Trends Genet.*, 5, 185 (1989)) utilizing primers prepared based on the nucleotide sequence of the gene, for example, the primers mentioned in Sequence Listing as SEQ ID NOS: 4 and 5, and chromosomal DNA of coryneform bacterium as a template. Genes coding for GS of other microorganisms can be obtained in a similar manner.

[0019] The chromosomal DNA can be prepared from a bacterium, which is a DNA donor, by the method of Saito and Miura (refer to H. Saito and K. Miura, *Biochem. Biophys. Acta*, 72, 619 (1963), Text for Bioengineering Experiments, Edited by the Society for Bioscience and Bioengineering, Japan, pp.97-98, Baifukan, 1992), for example.

[0020] Incidentally, an isozyme often exists for an enzyme involved in an amino acid biosynthesis system. The inventors of the present invention successfully isolated and cloned a gene coding for an isozyme of GS of coryneform bacteria by utilizing homology with respect to the nucleotide sequence of the aforementioned *glnA* gene. This gene is referred to as "*glnA2*". The process for obtaining it will be described later. *glnA2* as well as *glnA* can be used for enhancement of the GS activity of coryneform bacteria.

[0021] If the GS gene amplified by the PCR method is ligated to a vector DNA autonomously replicable in a cell of *Escherichia coli* and/or coryneform bacteria to prepare a recombinant DNA and this is introduced into *Escherichia coli*, subsequent procedures become easy. Examples of the vector autonomously replicable in a cell of *Escherichia coli* include pUC19, pUC18, pHSG299, pHSG399, pHSG398, RSF1010, pBR322, pACYC184, pMW219 and so forth.

[0022] A vector that functions in coryneform bacteria means, for example, a plasmid that can autonomously replicate in coryneform bacteria. Specific examples thereof include the followings.

pAM330 (refer to Japanese Patent Laid-open Publication No. 58-67699)

pHM1519 (refer to Japanese Patent Laid-open Publication No. 58-77895)

[0023] Moreover, if a DNA fragment having an ability to make a plasmid autonomously replicable in coryneform bacteria is taken out from these vectors and inserted into the aforementioned vectors for *Escherichia coli*, they can be used as a so-called shuttle vector autonomously replicable in both of *Escherichia coli* and coryneform bacteria.

[0024] Examples of such a shuttle vector include those mentioned below. There are also indicated microorganisms that harbor each vector, and accession numbers thereof at the international depositories are shown in the parentheses, respectively.

pAJ655	<i>Escherichia coli</i> AJ11882 (FERM BP-136) <i>Corynebacterium glutamicum</i> SR8201 (ATCC 39135)
pAJ1844	<i>Escherichia coli</i> AJ11883 (FERM BP-137) <i>Corynebacterium glutamicum</i> SR8202 (ATCC 39136)
pAJ611	<i>Escherichia coli</i> AJ11884 (FERM BP-138)
pAJ3148	<i>Corynebacterium glutamicum</i> SR8203 (ATCC 39137)
pAJ440	<i>Bacillus subtilis</i> AJ11901 (FERM BP-140)
pHC4	<i>Escherichia coli</i> AJ12617 (FERM BP-3532)

[0025] These vectors can be obtained from the deposited microorganisms as follows. That is, microbial cells collected in their exponential growth phase are lysed by using lysozyme and SDS, and centrifuged at 30000 x g. The supernatant obtained from the lysate is added with polyethylene glycol, fractionated and purified by cesium chloride-ethidium bromide equilibrium density gradient centrifugation.

5 [0026] In order to prepare a recombinant DNA by ligating a GS gene and a vector that can function in a cell of coryneform bacterium, a vector is digested with a restriction enzyme corresponding to the terminus of the gene containing the GS gene. Ligation is usually performed by using a ligase such as T4 DNA ligase.

[0027] To introduce the recombinant DNA prepared as described above into a microorganism, any known transformation methods that have hitherto been reported can be employed. For instance, employable are a method of treating
10 recipient cells with calcium chloride so as to increase the permeability of DNA, which has been reported for *Escherichia coli* K-12 (Mandel, M. and Higa, A., *J. Mol. Biol.*, 53, 159 (1970)), and a method of preparing competent cells from cells which are at the growth phase followed by introducing the DNA thereinto, which has been reported for *Bacillus subtilis* (Duncan, C.H., Wilson, G.A. and Young, F.E., *Gene*, 1, 153 (1977)). In addition to these, also employable is a method of making DNA-recipient cells into protoplasts or spheroplasts, which can easily take up recombinant DNA, followed
15 by introducing the recombinant DNA into the cells, which is known to be applicable to *Bacillus subtilis*, actinomycetes and yeasts (Chang, S. and Choen, S.N., *Molec. Gen. Genet.*, 168, 111 (1979); Bibb, M.J., Ward, J.M. and Hopwood, O.A., *Nature*, 274, 398 (1978); Hinnen, A., Hicks, J.B. and Fink, G.R., *Proc. Natl. Sci. USA*, 75, 1929 (1978)). The transformation of coryneform bacteria can also be performed by the electric pulse method (Sugimoto *et al.*, Japanese Patent Laid-open No. 2-207791).

20 [0028] Increase of copy number of GS gene can also be achieved by introducing multiple copies of the GS gene into chromosomal DNA of coryneform bacteria. In order to introduce multiple copies of the GS gene into chromosomal DNA of coryneform bacteria, homologous recombination is carried out by using a sequence whose multiple copies exist in the chromosomal DNA as targets. As sequences whose multiple copies exist in the chromosomal DNA, repetitive DNA, inverted repeats existing at the end of a transposable element can be used. Also, as disclosed in Japanese Patent
25 Laid-open No. 2-109985, it is possible to incorporate the GS gene into transposon, and allow it to be transferred to introduce multiple copies of the gene into the chromosomal DNA.

[0029] Enhancement of the GS activity can also be attained by, besides being based on the aforementioned gene amplification, replacing an expression control sequence of the GS gene on chromosomal DNA or plasmid, such as a promoter, with a stronger one. For example, *lac* promoter, *trp* promoter, *trc* promoter and so forth are known as strong
30 promoters. Moreover, it is also possible to introduce nucleotide substitution for several nucleotides into a promoter region for the GS gene so that it should be modified into a stronger one, as disclosed in International Patent Publication WO00/18935. By such substitution or modification of promoter, expression of the GS gene is enhanced and thus GS activity is enhanced. Such modification of expression control sequence may be combined with the increase of copy number of the GS gene.

35 [0030] The substitution of expression control sequence can be performed, for example, in the same manner as the gene substitution using a temperature sensitive plasmid described later. Examples of the temperature sensitive plasmid of coryneform bacteria include p48K, pSFKT2 (refer to Japanese Patent Laid-open Publication No. 2000-262288 for the both), pHSC4 (refer to France Patent Laid-open Publication No. 2667875, 1992 and Japanese Patent Laid-open Publication No. 5-7491) and so forth. These plasmids can at least autonomously replicate at a temperature of 25°C,
40 but cannot autonomously replicate at a temperature of 37°C in coryneform bacteria. Although pSFKT2 was used for the substitution for the promoter sequence of the GDH gene in the example mentioned later, gene substitution can be performed in a similar manner by using pHSC4 instead of pSFKT2. *Escherichia coli* AJ12571 harboring pHSC4 was deposited on October 11, 1990 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, the independent administrative corporation, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository (Chuo Dai-6, 1-1 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan, postal code: 305-8566)), and received an accession number of FERM P-11763. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on August 26, 1991, and received an accession number of FERM BP-3524.

45 [0031] Enhancement of the GS activity can be attained also by deficiency in regulation by the adenylation of intracellular GS, besides based on the increase of expression amount of the GS gene described above. GS changes into an inactive form by adenylation of a tyrosine residue in the amino acid sequence (*Proc. Natl. Acad. Sci. USA*, 642-649, (58) 1967; *J. Biol. Chem.*, 3769-3771, (243) 1968). Therefore, by defect of this adenylation of GS, the intracellular GS activity can be enhanced. The defect of adenylation used herein means not only substantially complete deregulation by the adenylation but also such reduction of the adenylation that the intracellular GS activity should be
55 enhanced.

[0032] The adenylation of GS is generally performed by adenylyl transferase (*Proc. Natl. Acad. Sci. USA*, 1703-1710, (58) 1967). It has been suggested that, in coryneform bacteria, the 405th tyrosine residue of the *glnA* gene product, which is represented by the sequence of Genebank accession Y13221, is adenylylated (FEMS Microbiology

Letters, 303- 310, 1999 (173)). This inactivation by the adenylylation of GS can be defected by introducing a mutation into the *glnA* gene so that the tyrosine residue should be replaced with another amino acid residue.

[0033] Further, the inactivation of GS by the adenylylation can also be defected by reducing the activities of intracellular glutamine synthetase adenylyl transferase (ATase). Although adenylyl transferase of coryneform bacteria had been unknown, the inventors of the present invention successfully isolated a gene coding for adenylyl transferase of coryneform bacteria, *glnE*. The process therefor will be described later.

[0034] To reduce the intracellular ATase activity of coryneform bacteria, there can be used, for example, a method of treating the coryneform bacteria by ultraviolet irradiation or with a mutagenizing agent used for usual mutagenesis treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or a nitrous acid and selecting a mutant strain in which the ATase activity is reduced. Coryneform bacteria having reduced ATase activity can also be obtained by gene disruption, besides the mutagenesis treatment. That is, a coryneform bacterium can be transformed with a DNA containing a *glnE* gene modified with deletion of partial sequence of the gene coding for ATase so as not to produce ATase functioning normally (deletion type *glnE* gene), so that recombination between the deletion type *glnE* gene and the *glnE* gene on the chromosome should occur to disrupt the *glnE* gene on the chromosome. Such gene disruption by gene substitution utilizing homologous recombination has already been established, and there are methods utilizing a linear DNA, a plasmid that contains a temperature sensitive replication origin and so forth.

[0035] A *glnE* gene on host chromosome can be replaced with the deletion type *glnE* gene, for example, as follows. That is, a recombinant DNA is prepared by inserting a temperature sensitive replication origin, a mutant *glnE* gene and a marker gene for resistance to a drug such as chloramphenicol, and a coryneform bacterium is transformed with the recombinant DNA. Further, the transformant is cultured at a temperature at which the temperature sensitive replication origin does not function, and then the transformant strain can be cultured in a medium containing the drug to obtain a transformant strain in which the recombinant DNA is incorporated into the chromosomal DNA.

[0036] In such a strain in which recombinant DNA is incorporated into chromosomal DNA as described above, the mutant *glnE* gene is recombined with the *glnE* gene originally present on the chromosome, and the two fusion genes of the chromosomal *glnE* gene and the deletion type *glnE* gene are inserted into the chromosome so that the other portions of the recombinant DNA (vector segment, temperature sensitive replication origin and drug resistance marker) should be present between the two fusion genes. Therefore, the transformant strain expresses normal ATase, because the normal *glnE* gene is dominant in this state.

[0037] Then, in order to leave only the deletion type *glnE* gene on the chromosomal DNA, one copy of the *glnE* gene is eliminated together with the vector segment (including the temperature sensitive replication origin and the drug resistance marker) from the chromosomal DNA by recombination of two of the *glnE* genes. In this case, the normal *glnE* gene is left on the chromosomal DNA, and the deletion type *glnE* gene is excised from the chromosomal DNA, or to the contrary, the deletion type *glnE* gene is left on the chromosomal DNA, and the normal *glnE* gene is excised from the chromosome DNA. In the both cases, the excised DNA may be retained in the cell as a plasmid when the cell is cultured at a temperature at which the temperature sensitive replication origin can function. Subsequently, if the cell is cultured at a temperature at which the temperature sensitive replication origin cannot function, the *glnE* gene on the plasmid is eliminated together with the plasmid from the cell. Then, a strain in which *glnE* gene is disrupted can be obtained by selecting a strain in which the deletion type *glnE* gene is left on the chromosome using PCR, Southern hybridization or the like.

[0038] Further, the inactivation of GS by the adenylylation can also be canceled by reducing the intracellular activity of PII protein. It is known that the PII protein is also involved in the adenylylation of GS by ATase. The PII protein is a signal transfer protein for controlling the GS activity, and it is known to be uridylylated by uridylyl transferase (UTase). The uridylylated PII protein promotes deadenylylation of GS by ATase, and the deuridylylated PII protein promotes the adenylylation of GS by ATase.

[0039] It is reported that GS is highly adenylylated in a UTase deficient strain (*J. Bacteriology*, 569-577, (134) 1978). This phenotype of excessive adenylylation is suppressed by mutation of the PII protein (*J. Bacteriology*, 816-822, (164) 1985). That is, the inactivation of GS by the adenylylation can also be defected by reduction of PII protein activity. The reduction of PII protein activity means reduction of the function for promoting the adenylylation by ATase. The *glnB* gene coding for the PII protein of coryneform bacteria has been already isolated, and it is suggested that the suppression of GS by the adenylylation of GS is defected by deletion of the gene (*FEMS Microbiology Letters*, 303-310, (173) 1999).

[0040] To reduce the PII protein activity of coryneform bacteria, there can be used, for example, a method of treating the coryneform bacteria by ultraviolet irradiation or with a mutagenizing agent used for usual mutagenesis treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or a nitrous acid and selecting a mutant strain in which the activity of PII protein is reduced. Coryneform bacteria having reduced PII protein activity can also be obtained by gene disruption, besides the mutagenesis treatment. That is, a coryneform bacterium can be transformed with DNA containing a *glnB* gene modified with deletion of partial sequence of the gene coding for PII protein so as not to produce PII protein functioning normally (deletion type *glnB* gene), so that recombination between the deletion type *glnB* gene and the *glnB* gene on the chromosome should occur to disrupt the *glnB* gene on the chromosome. Such gene destruction by

utilizing homologous recombination has already been established, and there are methods utilizing a linear DNA, a plasmid that contains a temperature sensitive replication origin and so forth.

[0041] A *glnB* gene on host chromosome can be replaced with the deletion type *glnB* gene, for example, as follows. That is, a recombinant DNA is prepared by inserting a temperature sensitive replication origin, a mutant *glnB* gene and a marker gene for resistance to a drug such as chloramphenicol, and a coryneform bacterium is transformed with the recombinant DNA. Further, the resultant transformant strain is cultured at a temperature at which the temperature sensitive replication origin does not function, and then the transformant strain can be cultured in a medium containing the drug to obtain a transformant strain in which the recombinant DNA is incorporated into the chromosomal DNA.

[0042] In such a strain in which recombinant DNA is incorporated into chromosomal DNA as described above, the mutant *glnB* gene is recombined with the *glnB* gene originally present on the chromosome, and the two fusion genes of the chromosomal *glnB* gene and the deletion type *glnB* gene are inserted into the chromosome so that the other portions of the recombinant DNA (vector segment, temperature sensitive replication origin and drug resistance marker) should be present between the two fusion genes. Therefore, the transformant expresses normal PII protein, because the normal *glnB* gene is dominant in this state.

[0043] Then, in order to leave only the deletion type *glnB* gene on the chromosomal DNA, one copy of the *glnB* gene is eliminated together with the vector segment (including the temperature sensitive replication origin and the drug resistance marker) from the chromosomal DNA by recombination of two of the *glnB* genes. In this case, the normal *glnB* gene is left on the chromosomal DNA, and the deletion type *glnB* gene is excised from the chromosomal DNA, or to the contrary, the deletion type *glnB* gene is left on the chromosomal DNA, and the normal *glnB* gene is excised from the chromosome DNA. In the both cases, the excised DNA may be stably retained in the cell as a plasmid when the cell is cultured at a temperature at which the temperature sensitive replication origin can function. Subsequently, if the cell is cultured at a temperature at which the temperature sensitive replication origin does not function, the *glnB* gene on the plasmid is eliminated together with the plasmid from the cell. Then, a strain in which *glnB* gene is disrupted can be obtained by selecting a strain in which the deletion type *glnB* gene is left on the chromosome using PCR, Southern hybridization or the like.

[0044] Elimination of the adenylation of GS can also be attained by a combination of two or three items of such mutation of GS that should eliminate the aforementioned adenylation, reduction of the ATase activity and reduction of the PII protein activity.

[0045] Although enhancement of the GS activity can also be realized by elimination of the adenylation of GS by ATase, it may also be attained by a combination of it with the aforementioned means for increasing copy number of the GS gene or means for modifying an expression control sequence.

[0046] In order to efficiently produce L-glutamine by using the coryneform bacterium of the present invention, it is preferable to use a strain that has enhanced glutamate dehydrogenase (henceforth also referred to as "GDH") activity concurrently with the enhanced GS activity.

[0047] The term "modified so that intracellular GDH activity should be enhanced" means that the GDH activity per cell has become higher than that of a non-modified strain, for example, a wild-type coryneform bacterium. For example, there can be mentioned a case where number of GDH molecules per cell increases, a case where GDH specific activity per GDH molecule increases and so forth. Further, as a wild-type coryneform bacterium that serves as an object for comparison, for example, the *Brevibacterium flavum* ATCC 14067 can be mentioned. As a result of enhancement of intracellular GDH activity, there are obtained an effect that culture time of a coryneform bacterium having L-glutamine producing ability is shortened.

[0048] Enhancement of the GDH activity in a coryneform bacterium cell can be attained by enhancement of expression of a gene coding for GDH. Enhancement of the expression amount of the gene can be attained by increasing copy number of the gene coding for GDH. For example, a recombinant DNA can be prepared by ligating a gene fragment coding for GDH with a vector functioning in the bacterium, preferably a multi-copy type vector, and introduced into a host having L-glutamine producing ability to transform it. Alternatively, the aforementioned recombinant DNA can be introduced into a wild-type coryneform bacterium to obtain a transformant strain, and then the obtained transformant strain can be imparted with L-glutamine producing ability.

[0049] As the gene coding for GDH, any of genes derived from coryneform bacteria and genes derived from other organisms such as bacteria belonging to the genus *Escherichia* can be used. Among these, genes derived from coryneform bacteria are preferred in view of ease of expression.

[0050] Nucleotide sequence of a gene coding for GDH (*gdh* gene) of coryneform bacteria has already been elucidated (*Molecular Microbiology*, 6 (3), 317-326 (1992)). Therefore, a GDH gene can be obtained by PCR utilizing primers prepared based on the nucleotide sequence, for example, the primers mentioned in Sequence Listing as SEQ ID NOS: 12 and 13, and chromosomal DNA of coryneform bacterium as a template. Genes coding for GDH of microorganisms other than coryneform bacteria can also be obtained in a similar manner.

[0051] The *gdh* gene can be introduced into coryneform bacteria in a manner similar to that used for the aforementioned GS gene.

[0052] In the coryneform bacterium of the present invention, activities of enzymes other than GS and GDH catalyzing reactions of the L-glutamine biosynthesis may be enhanced. Examples of the enzymes catalyzing reactions of the L-glutamine biosynthesis include isocitrate dehydrogenase, aconitate hydratase, citrate synthase, pyruvate dehydrogenase, phosphoenolpyruvate carboxylase, pyruvate carboxylase, pyruvate kinase, phosphofructokinase and so forth.

[0053] Further, activities of enzymes that catalyze reactions branching off from the L-glutamine biosynthesis pathway and producing compounds other than L-glutamine may be reduced or eliminated. Examples of the enzymes catalyzing such reactions include isocitrate lyase, α -ketoglutarate dehydrogenase, glutamate synthase and so forth.

(2) Production of L-glutamine using microorganism of the present invention

[0054] By culturing a coryneform bacterium obtained as described above in a medium to produce and accumulate L-glutamine in the medium and correcting the L-glutamine from the medium, L-glutamine can be efficiently produced and the by-production of L-glutamic acid can be suppressed.

[0055] In order to produce L-glutamine by using the coryneform bacterium of the present invention, culture can be performed in a conventional manner using a usual medium containing a carbon source, nitrogen source and mineral salts as well as organic trace nutrients such as amino acids and vitamins, as required. Either a synthetic medium or a natural medium may be used. Any kinds of carbon source and nitrogen source may be used so long as they can be utilized by a strain to be cultured.

[0056] As the carbon source, there are used sugars such as glucose, glycerol, fructose, sucrose, maltose, mannose, galactose, starch hydrolysate and molasses, and organic acids such as acetic acid and citric acid, and alcohols such as ethanol can also be used each alone or in a combination with other carbon sources.

[0057] As the nitrogen source, there are used ammonia, ammonium salts such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate and ammonium acetate, nitrate salts and so forth.

[0058] As the organic trace nutrients, amino acids, vitamins, fatty acids, nucleic acids, those containing those substances such as peptone, casamino acid, yeast extract and soybean protein decomposition product and so forth are used. When an auxotrophic mutant that requires an amino acid or the like for its growth is used, it is preferable to supplement the required nutrient.

[0059] As the mineral salts, phosphates, magnesium salts, calcium salts, iron salts, manganese salts and so forth are used.

[0060] The culture is performed as aeration culture, while the fermentation temperature is controlled to be 20-45°C, and pH to be 5-9. When pH falls during the culture, the medium is neutralized by addition of calcium carbonate or with an alkali such as ammonia gas. A substantial amount of L-glutamine is accumulated in the culture broth after 10 hours to 120 hours of culture in such a manner as described above.

[0061] Collection of L-glutamine from the culture broth after the culture may be performed in a conventional manner. For example, after the cells were removed from the culture broth, L-glutamine can be collected by concentrating the broth to crystallize L-glutamine.

(3) DNA coding for protein having glutamine synthetase activity (*glnA2* gene) and DNA coding for protein having glutamine synthetase and adenylyl transferase activities (*glnE* gene) according to the present invention

[0062] The first DNA of the present invention is a gene coding for GS. The second DNA of the present invention is a gene coding for ATase. These genes can be obtained from a chromosome DNA library of *Brevibacterium lactofermentum* by hybridization using a partial fragment of a known *glnA* gene as a probe. The partial fragment of a known *glnA* gene can be obtained by PCR amplification using chromosome DNA of *Brevibacterium lactofermentum*, for example, *Brevibacterium lactofermentum* ATCC 13869 strain, as a template and the primers shown as SEQ ID NOS: 18 and 19.

[0063] Methods of production of genomic DNA library, hybridization, PCR, preparation of plasmid DNA, digestion and ligation of DNA, transformation and so forth for obtaining the DNA of the present invention and enhancement of the GS activity and GDH activity are described in Sambrook, J., Fritsch, E.F. and Maniatis, T., "Molecular Cloning", Cold Spring Harbor Laboratory Press, 1.21, 1989.

[0064] The nucleotide sequences of the aforementioned primers were designed based on the nucleotide sequence of a *glnA* gene of *Corynebacterium glutamicum* (GenBank accession Y13221). By using these primers, a DNA fragment containing a region corresponding to the nucleotide numbers 1921-2282 of the *glnA* gene (GenBank accession Y13221) can be obtained.

[0065] Examples of nucleotide sequence of DNA fragment containing *glnA2* according to the present invention, which is obtained as described above, and amino acid sequence that can be encoded by the sequence are shown as SEQ ID NO: 1. Further, only an amino acid sequence of protein having glutamine synthetase activity, which is encoded by *glnA2*, is shown in SEQ ID NO: 2.

[0066] Further, in the aforementioned DNA fragment, another ORF was found immediately downstream from ORF of the *glnA2* gene. Based on homology comparison with respect to known sequences, that ORF was expected to be a gene (*glnE*) coding for a protein having glutamine synthetase adenylyl transferase activities (ATase). Only the amino acid sequence of the protein having the ATase activity is shown as SEQ ID NO: 3.

5 [0067] Nucleotide sequences of the DNA fragments containing *glnA2* or *glnE* according to the present invention were clarified by the present invention. Therefore, they can be isolated from chromosomal DNA of *Brevibacterium lactofermentum* by the PCR method using primers produced based on the nucleotide sequences.

[0068] The first DNA of the present invention may be one coding for glutamine synthetase including substitution, deletion, insertion, addition or inversion of one or several amino acids at one or more sites, so long as the glutamine synthetase activity of the encoded protein is not defected. Although the number of "several" amino acids referred to
10 herein differs depending on position or type of amino acid residues in the three-dimensional structure of the protein, it may be specifically 2 to 90, preferably 2 to 50, more preferably 2 to 20.

[0069] The second DNA of the present invention may be one coding for glutamine synthetase adenylyl transferase including substitution, deletion, insertion, addition or inversion of one or several amino acids at one or more sites, so long as the glutamine synthetase adenylyl transferase activities of the encoded protein are not defected. Although the number of "several" amino acids referred to herein differs depending on position or type of amino acid residues in the three-dimensional structure of the protein, it may be specifically 2 to 350, preferably 2 to 50, more preferably 2 to 20. Even in a case that the glutamine synthetase and adenylyl transferase activities are impaired, such a DNA fall within the scope of the present invention so long as it causes homologous recombination.

20 [0070] A DNA coding for the substantially same protein as the aforementioned GS or ATase can be obtained by, for example, modifying the nucleotide sequence of *glnA2* or *glnE* by means of the site-directed mutagenesis method so that one or more amino acid residues at a specified site should involve substitution, deletion, insertion, addition or inversion. A DNA modified as described above may also be obtained by a conventionally known mutagenesis treatment. The mutagenesis treatment includes a method of treating a DNA before the mutagenesis treatment in vitro with hydroxylamine or the like, and a method for treating a microorganism such as an genus *Escherichia* harboring a DNA before the mutagenesis treatment by ultraviolet irradiation or with a mutagenizing agent used for a usual mutagenesis treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and nitrous acid.

[0071] A DNA coding for substantially the same protein as glutamine synthetase or glutamine synthetase adenylyl transferase can be obtained by expressing a DNA having such a mutation as described above in an appropriate cell, and investigating activity of an expressed product. A DNA coding for substantially the same protein as GS or ATase can also be obtained by isolating a DNA that is hybridizable with a probe having a nucleotide sequence comprising, for example, the nucleotide sequence corresponding to nucleotide numbers of 659 to 1996 or 2066 to 5200 of the nucleotide sequence shown in Sequence Listing as SEQ ID NO: 1, under the stringent conditions, and codes for a protein having the glutamine synthetase or a protein having the glutamine synthetase adenylyl transferase activity, from DNA coding for glutamine synthetase or glutamine synthetase and adenylyl transferase having a mutation or from a cell harboring it. The "stringent conditions" referred to herein is a condition under which so-called specific hybrid is formed, and non-specific hybrid is not formed. It is difficult to clearly express this condition by using any numerical value. However, for example, the stringent conditions are exemplified by a condition under which DNAs having high homology, for example, DNAs having homology of not less than 50% are hybridized with each other, but DNAs having homology lower than the above are not hybridized with each other. Alternatively, the stringent conditions are exemplified by a condition under which DNAs are hybridized with each other at a salt concentration corresponding to an ordinary condition of washing in Southern hybridization, i.e., 1 x SSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS, at 60°C.

35 [0072] As a probe, a partial sequence of the nucleotide sequence of SEQ ID NO: 1 can also be used. Such a probe may be prepared by PCR using oligonucleotides produced based on the nucleotide sequence of SEQ ID NO: 1 as primers, and a DNA fragment containing the nucleotide sequence of SEQ ID NO: 1 as a template. When a DNA fragment in a length of about 300 bp is used as the probe, the conditions of washing for the hybridization consist of, for example, 50°C, 2 x SSC and 0.1% SDS.

[0073] Genes that are hybridizable under such conditions as described above includes those having a stop codon in the genes, and those having no activity due to mutation of active center. However, such mutation can be easily removed by ligating each gene with a commercially available activity expression vector, and measuring the glutamine synthetase or glutamine synthetase adenylyl transferase activities. The glutamine synthetase activity can be measured by, for example, the method described in *Methods in Enzymology*, Vol. XVIII, 910-915, ACADEMIC PRESS (1970), and the glutamine synthetase adenylyl transferase activities can be measured by, for example, the method described in *Methods in Enzymology*, Vol. XVIII, 922-923, ACADEMIC PRESS (1970). Even a DNA coding for glutamine synthetase adenylyl transferase of which activities are reduced or deleted can also be used in the present invention.

55 [0074] Specific examples of the DNA coding for a protein substantially the same as GS include DNA coding for a protein that has homology of preferably 80% or more, more preferably 85% or more, still more preferably 90% or more, with respect to the amino acid sequence shown as SEQ ID NO: 2 and has GS activity. Specific examples of the DNA

coding for a protein substantially the same as ATase include DNA coding for a protein that has homology of preferably 65% or more, more preferably 80% or more, still more preferably 90% or more, with respect to the amino acid sequence shown as SEQ ID NO: 3 and has ATase activity.

Best Mode for Carrying out the Invention

[0075] Hereafter, the present invention will be explained more specifically with reference to the following examples.

Example 1: Evaluation of GS gene-amplified strain

(1) Cloning of *glnA* gene of coryneform bacterium

[0076] The *glnA* sequence of *Corynebacterium glutamicum* had been already clarified (*FEMS Microbiology Letters*, 81-88, (154) 1997). Based on the reported nucleotide sequence, the primers shown in Sequence Listing as SEQ ID NOS: 4 and 5 were synthesized, and a *glnA* fragment was amplified by the PCR method using chromosome DNA of *Brevibacterium flavum* ATCC 14067 strain as a template.

[0077] The chromosomal DNA of *Brevibacterium flavum* ATCC 14067 strain was prepared by using Bacterial Genome DNA Purification Kit (Advanced Genetic Technologies Corp.). PCR was performed for 30 cycles each consisting of reactions at 94°C for 30 seconds for denaturation, at 55°C for 15 seconds for annealing and 72°C for 2 minutes for extension by using Pyrobest DNA Polymerase (Takara Shuzo).

[0078] The produced PCR product was purified in a conventional manner, digested with a restriction enzyme *Sall*, ligated with pMW219 (Nippon Gene) digested with *Sall* by using a ligation kit (Takara Shuzo), and used to transform competent cells of *Escherichia coli* JM109 (Takara Shuzo). The cells were plated on L medium containing 10 µg/ml of IPTG, 40 µg/ml of X-Gal and 25 µg/ml of kanamycin and cultured overnight. Then, the appeared white colonies were picked up and separated into single colonies to obtain transformants.

[0079] Plasmids are prepared from the transformants by the alkali method, and a plasmid in which the *glnA* gene was inserted into the vector was designated as pMW219GS.

(2) Construction of plasmid having *glnA* and replication origin of coryneform bacteria

[0080] Further, in order to construct a plasmid having the *glnA* gene and a replication origin of coryneform bacteria, the plasmid pHK4 (refer to Japanese Patent Laid-open Publication No. 5-7491) containing replication origin of the plasmid pHM1519 (*Agric. Biol. Chem.*, 48, 2901-2903 (1984)) that had been already obtained and was autonomously replicable in coryneform bacteria was digested with restriction enzymes *Bam*HI and *Kpn*I to obtain a gene fragment containing the replication origin. The obtained fragment was blunt-ended by using DNA Blunt-ending Kit (Takara Shuzo) and inserted into the *Kpn*I site of pMW219GS using a *Kpn*I linker (Takara Shuzo). This plasmid was designated as pGS.

(3) Introduction of pGS into coryneform bacterium and evaluation of culture

[0081] An L-glutamine producing bacterium, *Brevibacterium flavum* AJ12418 (FERM BP-2205: refer to Japanese Patent Laid-open Publication No. 2-186994), was transformed with the plasmid pGS by the electric pulse method (refer to Japanese Patent Laid-open Publication No. 2-207791) to obtain a transformant. By using the obtained transformant AJ12418/pGS, culture for L-glutamine production was performed as follows.

[0082] Cells of AJ12418/pGS strain obtained by culture on a CM2B plate medium containing 25 µg/ml of kanamycin were inoculated into a medium containing 100 g of glucose, 60 g of (NH₄)₂SO₄, 2.5 g of KH₂PO₄, 0.4 g of MgSO₄·7H₂O, 0.01 g of FeSO₄·7H₂O, 350 µg of VB₁-HCl, 4 µg of biotin, 200 mg of soybean hydrolysates and 50 g of CaCO₃ in 1 L of pure water (adjusted to pH 6.8 with NaOH) and cultured at 31.5°C with shaking until the sugar in the medium was consumed.

[0083] After the completion of the culture, the amount of accumulated L-glutamine in the culture broth was analyzed by liquid chromatography for appropriately diluted culture broth. CAPCELL PAK C18 (Shiseido) was used as a column, and the sample was eluted with an eluent containing 0.095% phosphoric acid, 3.3 mM heptanesulfonic acid and 5% acetonitrile in 1 L of distilled water. The accumulated L-glutamine amount was analyzed based on variation of absorbance at 210 nm. The results of this analysis are shown in Table 1.

Table 1

Strain	L-Gln (g/L)	L-Glu (g/L)	culture time (hr)
AJ12418	38.4	0.7	70

Table 1 (continued)

Strain	L-Gln (g/L)	L-Glu (g/L)	culture time (hr)
AJ12418/pGS	45.1	0.02	82

[0084] In the pGS-introduced strain, accumulation of L-glutamine (L-Gln) was markedly improved, and by-production of L-glutamic acid (L-Glu), was considerably suppressed. From these results, it was demonstrated that enhancement of GS was effective for improvement of yield in the production of L-glutamine. The data for the enzymatic activity of GS are shown in Table 2 of Example 2.

Example 2: Evaluation of GS adenylylation site-modified strain

(1) Construction of adenylylation site-modified plasmid

[0085] The adenylylation site of *glnA* gene product of coryneform bacteria had been already clarified (*FEMS Microbiology Letters*, 303-310, (173) 1999). Therefore, an adenylylation site-modified strain was obtained by replacing the *glnA* gene on the chromosome with a *glnA* gene of which adenylylation site was modified. Specific procedures will be described below.

[0086] First, PCR was performed by using chromosome DNA of *Brevibacterium flavum* ATCC 14067 strain as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 6 and 7 as primers to obtain an amplification product for the N-terminus side of the *glnA* gene. Separately, in order to obtain an amplification product for the C-terminus side of the *glnA* gene, PCR was performed by using chromosome DNA of *Brevibacterium flavum* ATCC 14067 strain as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 8 and 9 as primers. Since mismatches were introduced into the sequences shown in Sequence Listing as SEQ ID NOS: 7 and 8, a mutation was introduced into the terminal portion of each of the amplification products. Then, in order to obtain a *glnA* gene fragment introduced with a mutation, PCR was performed by using the aforementioned gene products for N- and C-terminus sides of *glnA* mixed in equimolar amounts as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 10 and 11 as primers to obtain a *glnA* gene amplification product introduced with a mutation at the adenylylation site. The produced PCR product was purified in a conventional manner, digested with *Hind*III and inserted into the *Hind*III site of pHSG299 (Takara Shuzo). This plasmid was designated as pGSA.

(2) Construction of adenylylation site-modified strain and evaluation of culture

[0087] Since the above pGSA does not contain a region that enables its autonomous replication within cells of coryneform bacteria, when a coryneform bacterium is transformed with this plasmid, a strain in which the plasmid is incorporated into chromosome by homologous recombination is obtained as a transformant although it occurs at an extremely low frequency.

[0088] The L-glutamine producing bacterium, *Brevibacterium flavum* AJ12418, was transformed with the plasmid pGSA at a high concentration by the electric pulse method (refer to Japanese Patent Laid-open Publication No. 2-207791), and transformants were obtained by using kanamycin resistance as a marker. Then, these transformants were subcultured and strains that became kanamycin sensitive were obtained. Further, the sequences of *glnA* gene of the kanamycin sensitive strains were determined, and a strain in which the adenylylation site in the sequence was replaced with that region of *glnA* derived from pGSA was designated as QA-1. Culture for L-glutamine production was performed in the same manner as described in Example 1, (3) using AJ12418, AJ12418/pGS and QA-1 strains. The results are shown in Table 2.

Table 2

Strain	L-Gln (g/L)	GS activity (U/mg)	Culture time (hr)
AJ12418	39.0	0.030	70
AJ12418/pGS	46.1	0.067	81
QA-1	44.3	0.040	72

[0089] For the QA-1 strain, improvement of L-glutamine accumulation was observed compared with AJ12418.

[0090] The results for measurement of GS activity of these strains are also shown in Table 2. The GS activity was measured by adding a crude enzyme solution to a solution containing 100 mM imidazole-HCl (pH 7.0), 0.1 mM NH_4Cl , 1 mM MnCl_2 , 1 mM phosphoenolpyruvic acid, 0.3 mM NADH, 10 U of lactate dehydrogenase, 25 U of pyruvate kinase,

1 mM ATP and 10 mM MSG and measuring variation of absorbance at 340 nm at 30°C referring to the method described in *Journal of Fermentation and Bioengineering*, Vol. 70, No. 3, 182-184, 1990. For the measurement of blank, the aforementioned reaction solution not containing MSG was used. The crude enzyme solution was prepared by separating cells from the aforementioned culture broth by centrifugation, washing the cells with 100 mM imidazole-HCl (pH 7.0), sonicating the cells and removing undisrupted cells and insoluble protein by centrifugation. Protein concentration of the crude enzyme solution was quantified with Protein Assay (Bio-Rad) by using bovine serum albumin as a standard sample.

Example 3: Evaluation of GDH gene-amplified strain

(1) Construction of *gdh*-amplified strain and evaluation of culture

[0091] Construction of a plasmid pGDH into which the *gdh* gene of coryneform bacteria was cloned was performed as follows. First, chromosome DNA of *Brevibacterium lactofermentum* ATCC 13869 strain was extracted, and PCR was performed by using the chromosome DNA as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 12 and 13 as primers. The obtained DNA fragment was blunt-ended and inserted into the *Sma*I site of pHSG399 (Takara Shuzo). This plasmid was designated as pHSG399GDH.

[0092] Then, a replication origin derived from the plasmid pHM1519 (*Agric. Biol. Chem.*, 48, 2901-2903 (1984)) that could autonomously replicate in coryneform bacteria was introduced into the *Sa*I site of pHSG399GDH. Specifically, the aforementioned pHK4 was digested with restriction enzymes *Bam*HI and *Kpn*I to obtain a gene fragment containing the replication origin, and the obtained fragment was blunt-ended and inserted into the *Sa*I site of pHSG399GDH by using an *Sa*I linker (Takara Shuzo). This plasmid was designated as pGDH.

[0093] The L-glutamine producing bacterium, *Brevibacterium flavum* AJ12418 strain, was transformed with pGDH to obtain a transformant. Culture for L-glutamine production was performed by the method described in Example 1 using the obtained transformant AJ12418/pGDH. The results are shown in Table 3. In the GDH-enhanced strain, yield of L-glutamine decreased and by-production of L-glutamic acid increased, but culture time was considerably shortened.

Table 3

Strain	L-Gln (g/L)	L-Glu (g/L)	Culture time (hr)
AJ12418	38.8	0.7	70
AJ12418/pGDH	29.5	12.0	55

Example 4: Construction and evaluation of strain in which GS and GDH are enhanced simultaneously

(1) Construction of *gdh* promoter-modified plasmid

[0094] Chromosomal DNA of *Brevibacterium flavum* ATCC 14067 strain was extracted, and PCR was performed by using the chromosomal DNA as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 14 and 15 as primers. The obtained DNA fragment was digested with restriction enzymes *Stu*I and *Pvu*II and inserted into the *Sma*I site of pHSG399. This plasmid was digested with a restriction enzyme *Sac*I to obtain a DNA fragment containing the *gdh* promoter and a partial fragment of the *gdh* gene, and it was inserted into the *Sac*I site of pKF19K (Takara Shuzo). This plasmid was designated as pKF19GDH.

[0095] A mutation was introduced into the promoter region by using Mutan-Super Express Km (Takara Shuzo). LA-PCR was performed by using pKF19GDH as a template, a selection primer attached to Mutan-super Express Km and a 5'-end phosphorylated synthetic DNA shown in Sequence Listing as SEQ ID NO: 16 or 17 as a primer for mutagenesis. The reaction product was purified by ethanol precipitation, and competent cells of *Escherichia coli* MV1184 (Takara Shuzo) were transformed with the product to obtain transformants.

[0096] Plasmids were extracted from the transformants, and sequences of the *gdh* promoter region were determined. Among these, those having the sequences shown in Table 4 were designated as pKF19GDH1 and pKF19GDH4. It is expected that the GDH activity can be improved by about 3 times by replacing the *gdh* promoter sequence with that of pKF19GDH1 type, or by about 5 times by replacing the *gdh* promoter sequence with that of pKF19GDH4 type, compared with *gdh* having a promoter of a wild-type (refer to International Patent Publication WO00/18935).

[0097] These plasmids were digested with a restriction enzyme *Sac*I to obtain a DNA fragment containing the *gdh* promoter and a partial fragment of the *gdh* gene, and it was inserted into the *Sac*I site of pSFKT2 (refer to Japanese Patent Laid-open Publication No. 2000-262288). These plasmids were designated as pSFKTGDH1 and pSFKTGDH4, respectively. pSFKT2 was a derivative of the plasmid pAM330 derived from the *Brevibacterium lactofermentum* ATCC 13869 strain, and it is a plasmid of which autonomous replication in coryneform bacteria has become temperature

sensitive.

Table 4

Plasmid	<i>gdh</i> promoter sequence
pKF19GDH	TGGTCAtatctgtgCGacgctgcCATAAT (SEQ ID NO: 20)
pKF19GDH1	TGGTCAtatctgtgCGacgctgcTATAAT (SEQ ID NO: 21)
pKF19GDH4	TTGCCAtatctgtgCGacgctgcTATAAT (SEQ ID NO: 22)

(2) Introduction of *gdh* promoter mutation into chromosome

[0098] A mutation was introduced into the *gdh* promoter sequence on chromosome as follows. First, the QA-1 strain was transformed with the plasmid pSFKTGDH1 or pSFKTGDH4 by the electric pulse method to obtain a transformant, respectively. After the transformation, culture was performed at 25°C. Then, these transformants were cultured at 34°C, and strains showing kanamycin resistance at 34°C were selected. Since the aforementioned plasmids cannot autonomously replicate at 34°C, only those in which these plasmids were integrated into chromosome by homologous recombination show kanamycin resistance. Further, the strains in which these plasmids were integrated into chromosome were cultured in the absence of kanamycin, and strains that became kanamycin sensitive were selected. Among those, strains in which the same mutation as that of pSFKTGDH1 or pSFKTGDH4 was introduced into the *gdh* promoter region on the chromosome were designated as QB-1 and QB-4, respectively.

(3) Construction of *gdh* gene-amplified strain and measurement of GDH activity

[0099] The L-glutamine producing bacterium, *Brevibacterium flavum* QA-1 strain, was transformed with the plasmid pGDH described in Example 3, (2) to obtain a transformant. Culture for L-glutamine production was performed by the method described in Example 1 using the obtained transformant QA-1/pGDH. The GDH activity was measured by adding a crude enzyme solution to a solution containing 100 mM Tris-HCl (pH 7.5), 20 mM NH₄Cl, 10 mM α -ketoglutaric acid and 0.25 mM NADPH and measuring change of absorbance at 340 nm referring to *Mol. Microbiology*, 317-326 (6) 1992. The crude enzyme solution was prepared by separating cells from the aforementioned culture broth by centrifugation, washing the cells with 100 mM Tris-HCl (pH 7.5), sonicating the cells and removing undisrupted cells by centrifugation. Protein concentration of the crude enzyme solution was quantified with Protein Assay (Bio-Rad) by using bovine serum albumin as a standard sample. The results are shown in Table 5.

[0100] As for yield of L-glutamine, the GDH promoter-modified strains, QB-1 and QB-4, showed high yield. Further, the QA-1/pGDH strain also showed higher yield than that obtained with the AJ12418 strain. The culture time of the QA-1/pGDH strain was the shortest. The by-production of L-glutamic acid was markedly improved in the QB-1 and QB-4 strains. From these results, it was demonstrated that the simultaneous enhancement of GS and GDH was effective for improvement of yield of L-glutamine and shortening of culture time.

Table 5

Strain	L-Gln (g/L)	L-Glu (g/L)	Culture time (hr)	GDH activity (U/mg)
AJ12418	40.5	0.8	68	1.6
QA-1/pGDH	47.9	1.0	60	15.2
QB-1	50.5	0.1	65	4.1
QB-4	50.0	0.3	65	9.6

Example 5: Acquisition of gene coding for isozyme of GS

[0101] In the paper that reported acquisition of *glnA* of *Corynebacterium glutamicum* (*FEMS Microbiol. Letter*, 154 (1997) 81-88), it is described that a Δ *glnA*-disrupted strain became to show glutamine auxotrophy and lost the GS activity, and it also reported data showing results of Southern blotting and suggesting existence of an isozyme. Further, "Amino Acid Fermentation", Japan Science Societies Publication (Gakkai Shuppan Center), pp.232-235 describes that there are two kinds of GS for *Corynebacterium glutamicum*. Therefore, it was attempted to obtain a gene coding for the second GS isozyme.

(1) Preparation of probe

[0102] A gene coding for an isozyme of GS (*glnA2*) was obtained by colony hybridization. First, PCR was performed by using the primers shown in Sequence Listing as SEQ ID NOS: 18 and 19 and chromosomal DNA of the *Brevibacterium lactofermentum* ATCC 13869 strain as a template to obtain a partial fragment of the *glnA* gene. This DNA fragment was labeled by using DIG-High Prime DNA Labeling & Detection Starter Kit I (Boehringer Mannheim) and used as a probe.

(2) Colony hybridization

[0103] Chromosomal DNA of the *Brevibacterium lactofermentum* ATCC 13869 strain was extracted and partially digested with a restriction enzyme *Sau3AI*, and the obtained DNA fragment was inserted into the *BamHI* site of the vector of pHSG299 and used to transform the *Escherichia coli* JM109 strain. The obtained transformant was transferred to Hybond-N+ (Amersham Pharmacia Biotech), denatured, neutralized and then hybridized with the probe prepared in Example 5, (1) by using DIG-High Prime DNA Labeling & Detection Starter Kit I. At this time, a transformant that hybridized strongly and a transformant that hybridized weakly were recognized. Plasmid DNAs were prepared from these transformants and nucleotide sequences of inserts were determined. As a result, clones containing a gene showing high homology with respect to a known glutamine synthetase of coryneform bacteria could be obtained. The total nucleotide sequence of the insert of the latter was shown in Sequence Listing as SEQ ID NO: 1.

[0104] Open reading frames were deduced, and amino acid sequences deduced from the nucleotide sequences were shown in Sequence Listing as SEQ ID NOS: 2 and 3. Each of these amino acid sequences was compared with known sequences for homology. The used database was Genbank. As a result, it became clear that the amino acid sequences encoded by the both of the open reading frames were novel proteins of coryneform bacteria.

[0105] The nucleotide sequences and the amino acid sequences were analyzed by using Genetyx-Mac computer program (Software Development, Tokyo). The homology analysis was performed according to the method of Lipman and Pearson (*Science*, 227, 1435-1441, 1985).

[0106] The amino acid sequence shown in Sequence Listing as SEQ ID NO: 2 showed 34.6%, 65.6% and 60% of homology with respect to already reported GS of *Corynebacterium glutamicum* (FEMS Microbiology Letters, 81-88, (154) 1997), GS of *Mycobacterium tuberculosis* (GenBank accession Z70692) and GS of *Streptomyces coelicolor* (GenBank accession AL136500), respectively (Table 6), and it was found to be an isozyme of GS of coryneform bacteria.

[0107] On the other hand, the sequence shown in Sequence Listing as SEQ ID NO: 3 showed 51.9% and 33.4% of homology with respect to the already reported ATase of *Mycobacterium tuberculosis* (GenBank accession Z70692) and ATase of *Streptomyces coelicolor* (GenBank accession Y17736), respectively (Table 7), and it was found to be ATase of coryneform bacteria. Therefore, it was found that, in the nucleotide sequence shown as SEQ ID NO: 1, the open reading frame coding for the amino acid sequence shown as SEQ ID NO: 2 was *glnA2*, and the open reading frame coding for the amino acid sequence shown as SEQ ID NO: 3 was *glnE*.

Table 6

Strain	Gene name	Amino acid Number	Homology
<i>Brevibacterium lactofermentum</i>	<i>glnA2</i>	446 A.A.	--
<i>Corynebacterium glutamicum</i>	<i>glnA</i>	478 A.A.	34.6%
<i>Mycobacterium tuberculosis</i>	<i>glnA2</i>	446 A.A.	65.6%
<i>Streptomyces coelicolor</i>	<i>glnA</i>	453 A.A.	60.0%

Table 7

Strain Strain	Gene name	Amino acid number	Homology Homology
<i>Brevibacterium lactofermentum</i>	<i>glnE</i>	1045 A.A.	--
<i>Mycobacterium tuberculosis</i>	<i>glnE</i>	994 A.A.	51.9%
<i>Streptomyces coelicolor</i>	<i>glnE</i>	784 A.A.	33.4%

Example 6: Production of L-glutamine by ATase-deficient strain

[0108] Since the gene *glnE* coding for ATase was elucidated in the aforementioned Example 5, a *glnE*-deficient strain was constructed from the L-glutamine producing bacterium AJ12418. The specific procedure will be shown below.

[0109] First, PCR was performed by using chromosome DNA of *Brevibacterium flavum* ATCC 14067 strain as a template and the synthetic DNAs of SEQ ID NOS: 23 and 24 as primers to obtain a partial fragment of *glnE* gene. The produced PCR product was purified in a conventional manner, then blunt-ended and inserted into the HincII site of pHSG299 (Takara Shuzo). This plasmid was designated as pGLNE. Then, in order to delete a partial region of the *glnE* gene in this plasmid, pGLNE was digested with *Hind*III and self-ligated, and the obtained plasmid was designated as pΔGLNE. This plasmid contained the 2341st to 4650th nucleotides of the nucleotide sequence shown in Sequence Listing as SEQ ID NO: 1, but it had deletion of about 300 bp from the 3343rd HincII recognition site to the 3659th HincII recognition site.

[0110] Since the above pΔGLNE does not contain a region that enables its autonomous replication within cells of coryneform bacteria, when a coryneform bacterium is transformed with this plasmid, a strain in which the plasmid is integrated into chromosome by homologous recombination may be produced as a transformant although it occurs at an extremely low frequency.

[0111] The L-glutamine producing bacterium, *Brevibacterium flavum* AJ12418, was transformed with the plasmid pΔGLNE at a high concentration by the electric pulse method, and transformants were obtained by using kanamycin resistance as a marker. Then, these transformants were subcultured to obtain strains that became kanamycin sensitive. Further, chromosomal DNAs of the obtained kanamycin sensitive strains were extracted, and PCR was performed by using each chromosomal DNA as a template and the synthetic DNAs shown in Sequence Listing as SEQ ID NOS: 23 and 24 as primers to obtain partial fragments of the *glnE* gene. A strain of which PCR product did not provide about 300 bp fragment when it was digested with *Hind*III was determined as a *glnE*-disrupted strain. This strain was designated as QA-T. Culture for L-glutamine production was performed in the same manner as described in Example 1,

(3) by using AJ12418 and QA-T strains. The results are shown in Table 8.

[0112] The QA-T strain showed improvement of L-glutamine accumulation compared with the AJ12418 strain. The results of measurement of the GS activity of these strains are also shown in Table 8. It was confirmed that the GS activity was improved in the QA-T strain compared with the AJ12418 strain.

Table 8

Strain	L-Gln (g/L)	GS activity (U/mg)	Culture time (hr)
AJ12418	39.0	0.03	70
QA-T	45.1	0.05	75

(EXPLANATION OF SEQUENCE LISTING)

[0113]

SEQ ID NO: 1: *glnA2* And *glnE* nucleotide sequences

SEQ ID NO: 2: *glnA2* amino acid sequence

SEQ ID NO: 3: *glnE* amino acid sequence

SEQ ID NO: 4: Primer N for *glnA* amplification

SEQ ID NO: 5: Primer C for *glnA* amplification

SEQ ID NO: 6: *glnA* 1st PCR primer NN

SEQ ID NO: 7: *glnA* 1st PCR primer NC

SEQ ID NO: 8: *glnA* 1st PCR primer CN

SEQ ID NO: 9: *glnA* 1st PCR primer CC

SEQ ID NO: 10: *glnA* 2nd PCR primer N

SEQ ID NO: 11: *glnA* 2nd PCR primer C

SEQ ID NO: 12: Primer N for *gdh* amplification

SEQ ID NO: 13: Primer C for *gdh* amplification

SEQ ID NO: 14: Primer N2 for *gdh* amplification

SEQ ID NO: 15: Primer C2 for *gdh* amplification

SEQ ID NO: 16: Primer M1 for *gdh* promoter mutation

SEQ ID NO: 17: Primer M4 for *gdh* promoter mutation

SEQ ID NO: 18: Primer N for *glnA* probe preparation

SEQ ID NO: 19: Primer C for *glnA* probe preparation

SEQ ID NO: 20: Wild-type *gdh* promoter sequence

SEQ ID NO: 21: Mutant type *gdh* promoter sequence

EP 1 229 121 A2

SEQ ID NO: 22: Mutant type *gdh* promoter sequence

SEQ ID NO: 23: Primer N for *glnE* disruption

SEQ ID NO: 24: Primer C for *glnE* disruption

5

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> Ajinomoto Co., Inc.

 <120> Method for Producing L-Glutamine by Fermentation
10 and L-Glutamine Producing Bacterium

 <130> OP1288

15 <140>

 <141> 2001-05-30

20 <150> JP 2001-28163

 <151> 2001-02-05

25 <150> JP 2001-162806

 <151> 2001-05-30

30 <160> 24

35 <170> PatentIn version 3.0

 <210> 1

40 <211> 5500

 <212> DNA

 <213> Brevibacterium lactofermentum

45 <220>

 <221> CDS

50 <222> (659)..(1996)

 <220>

55 <221> CDS

<222> (2006).. (5200)

5	<400> 1	
	galcaglgci tcggcttctt cticgaagtt ggtggactct gcccttttca aaagtgcggt	60
	galacgaiga tgcgcttggg cctiglgccgg ggtcattggg ctgggtctt galigctaa	120
	ggcglggagc tcigcgagca ttgccagtc aggaaggla cttagcttcg glagctcgt	180
10	gagaacttc tccagggtca tcaccggcaa gggctagtt tcggcggcac gcgtccgtt	240
	cacccacagt ggtacatct calcgagca ggaglaagca atctcaggla gcgcglgaaa	300
	caggagtgga lcaatalcgg cggaaaactc atggcggaga tcggcgggag tccaccacg	360
15	aagcgacag aaacctaggt ggctgaatg gcttcttctt aaaatctgac gglaagagtc	420
	ttgtgcgtcg gtgacgtgt cggagaagtg ggagagggtc attgcggttt ccttattcgt	480
	aggagagttc taatttcgtt gcggttctca gtaaccacc caagcggac acctccacc	540
	cccgltcat caaaaaaccg cgacatctt gaglaactct gaaaaaact acccccgatg	600
20	cgagialaaa agtggcaaat gcgcagtcga tctccatcg ctgcglagat tagtttc	658
	atg aac agc gaa cag gaa ttt gta ctg agc gcc att gaa gaa cgc gac	706
	Met Asn Ser Glu Gln Glu Phe Val Leu Ser Ala Ile Glu Glu Arg Asp	
	1 5 10 15	
25	att aag ttt gtg cgt cta tgg ttc act gac att ctt gga cac ttg aag	754
	Ile Lys Phe Val Arg Leu Trp Phe Thr Asp Ile Leu Gly His Leu Lys	
	20 25 30	
	tca gtg gtt gtg gct cct gca gaa cta gag tct gcg ttg gaa gaa ggc	802
30	Ser Val Val Val Ala Pro Ala Glu Leu Glu Ser Ala Leu Glu Glu Gly	
	35 40 45	
	atc gga ttc gal ggc tca gcc att gag ggc tac gcg cgt atc tgc gaa	850
35	Ile Gly Phe Asp Gly Ser Ala Ile Glu Gly Tyr Ala Arg Ile Ser Glu	
	50 55 60	
	gcg gac acc att gcc cgc cca gat cca tgc aca ttc cag gtc ctg cca	898
	Ala Asp Thr Ile Ala Arg Pro Asp Pro Ser Thr Phe Gln Val Leu Pro	
40	65 70 75 80	
	cta gaa gcg ggc atc tca aaa ctg cag gca gca cgc ctg ttt tgc gat	946
	Leu Glu Ala Gly Ile Ser Lys Leu Gln Ala Ala Arg Leu Phe Cys Asp	
	85 90 95	
45	gtc acg atg ccg gac gga cag cca tct ttt tct gac ccg cgc caa gtg	994
	Val Thr Met Pro Asp Gly Gln Pro Ser Phe Ser Asp Pro Arg Gln Val	
	100 105 110	
	ctg cgc agg cag gtc caa cta gct gca gat gaa ggc ttg acc tgc atg	1042
50	Leu Arg Arg Gln Val Gln Leu Ala Ala Asp Glu Gly Leu Thr Cys Met	
	115 120 125	
	atc tca cca gag att gag ttc tat ttg gtg caa agc ctt cgc acc aac	1090
55	Ile Ser Pro Glu Ile Glu Phe Tyr Leu Val Gln Ser Leu Arg Thr Asn	
	130 135 140	

EP 1 229 121 A2

	gga ctg cca cct glg ccc act gac aac ggc gga tat ttc gac caa gcc	1138
	Gly Leu Pro Pro Val Pro Thr Asp Asn Gly Gly Tyr Phe Asp Gln Ala	
5	145 150 155 160	
	aca ttc aat gag gcg ccg aat ttc cgt cga aac gcg atg gta gcg ctg	1186
	Thr Phe Asn Glu Ala Pro Asn Phe Arg Arg Asn Ala Met Val Ala Leu	
	165 170 175	
10	gag gaa ctg ggc atc cct gtc gag ttc tcc cac cat gaa act gca cct	1234
	Glu Glu Leu Gly Ile Pro Val Glu Phe Ser His His Glu Thr Ala Pro	
	180 185 190	
15	ggc cag caa gaa atc gat tta cgc cat gcg gat gcg ctg acc atg gcc	1282
	Gly Gln Gln Glu Ile Asp Leu Arg His Ala Asp Ala Leu Thr Met Ala	
	195 200 205	
	gac aac atc atg acc ttc cgc tac atc atg aaa cag gtg gca agg gac	1330
20	Asp Asn Ile Met Thr Phe Arg Tyr Ile Met Lys Gln Val Ala Arg Asp	
	210 215 220	
	caa ggc gtt ggg gca tca ttt atg ccc aag cca ttc caa gaa cat gca	1378
	Gln Gly Val Gly Ala Ser Phe Met Pro Lys Pro Phe Gln Glu His Ala	
25	225 230 235 240	
	ggc tcc gcc atg cac acg cac atg tcc tta ttt gag ggc gat acc aac	1426
	Gly Ser Ala Met His Thr His Met Ser Leu Phe Glu Gly Asp Thr Asn	
	245 250 255	
30	gcg ttc cac gat cca gac gat tct tac atg ctg tcc aaa acc gca aaa	1474
	Ala Phe His Asp Pro Asp Asp Ser Tyr Met Leu Ser Lys Thr Ala Lys	
	260 265 270	
	cag ttc atc gct gga atc ttg cat cac gct cca gaa ttc acc gct gtg	1522
35	Gln Phe Ile Ala Gly Ile Leu His His Ala Pro Glu Phe Thr Ala Val	
	275 280 285	
	acc aac cag tgg gtc aat tcc tac aaa cgc atc gtg tac gga aac gaa	1570
	Thr Asn Gln Trp Val Asn Ser Tyr Lys Arg Ile Val Tyr Gly Asn Glu	
40	290 295 300	
	gct cca act gcg gca acc tgg ggt gta tct aat cgt tct gcg ctg gtt	1618
	Ala Pro Thr Ala Ala Thr Trp Gly Val Ser Asn Arg Ser Ala Leu Val	
45	305 310 315 320	
	cgt gtt cct acc tac cgt ttg aat aag gag gag tgg cgc cgg gtg gag	1666
	Arg Val Pro Thr Tyr Arg Leu Asn Lys Glu Glu Ser Arg Arg Val Glu	
	325 330 335	
50	gtg cgt ctt cct gat acc gct tgt aac cca tat ttg gcg ttt tca gtg	1714
	Val Arg Leu Pro Asp Thr Ala Cys Asn Pro Tyr Leu Ala Phe Ser Val	
	340 345 350	
55	atg ctg ggc gct ggt ttg aaa ggt att aaa gaa ggt tat gag ctg gac	1762
	Met Leu Gly Ala Gly Leu Lys Gly Ile Lys Glu Gly Tyr Glu Leu Asp	

	355	360	365	
	gag cca gct gag gac gat atc tcc aac ttg agc ttc cgg gaa cgt cgc	1810		
5	Glu Pro Ala Glu Asp Asp Ile Ser Asn Leu Ser Phe Arg Glu Arg Arg			
	370	375	380	
	gcc atg ggc tac aac gat ctg cca aac agc ctt gat cag gca ctg cgc	1858		
10	Ala Met Gly Tyr Asn Asp Leu Pro Asn Ser Leu Asp Gln Ala Leu Arg			
	385	390	395	400
	caa atg gaa aag tca gag ctt gtt gct gac atc ctc ggt gag cac gtt	1906		
15	Gln Met Glu Lys Ser Glu Leu Val Ala Asp Ile Leu Gly Glu His Val			
	405	410	415	
	ttt gag ttt ttc ttg cgc aat aag tgg cgt gaa tgg cgt gac tac caa	1954		
	Phe Glu Phe Phe Leu Arg Asn Lys Trp Arg Glu Trp Arg Asp Tyr Gln			
	420	425	430	
20	gag cag atc act ccg tgg gag ctc cga aac aat ctt gat tac tagactttt	2005		
	Glu Gln Ile Thr Pro Trp Glu Leu Arg Asn Asn Leu Asp Tyr			
	435	440	445	
25	gcactccaal ggaaacccta cggcgaccca attgcgaccc gataaaggag gggagaagct	2065		
	atg tca gga ccg tta aga agt gaa cgt aaa gtc gtt ggc ttt gtc aga	2113		
	Met Ser Gly Pro Leu Arg Ser Glu Arg Lys Val Val Gly Phe Val Arg			
	1	5	10	15
30	gac cca ctg cca aaa gtt ggt tct tta tct ctg aaa tct gag cat gcc	2161		
	Asp Pro Leu Pro Lys Val Gly Ser Leu Ser Leu Lys Ser Glu His Ala			
	20	25	30	
	caa gca gat cta gag cat ttg ggt tgg cgc aat gtt gag tct ttg gat	2209		
35	Gln Ala Asp Leu Glu His Leu Gly Trp Arg Asn Val Glu Ser Leu Asp			
	35	40	45	
	ttg ttg tgg ggc ttg tca ggt gca ggc gat ccc gat gtc gcg ctg aac	2257		
40	Leu Leu Trp Gly Leu Ser Gly Ala Gly Asp Pro Asp Val Ala Leu Asn			
	50	55	60	
	ctt ctt att cgg ctg tat cag gca ctt gaa gca atc ggc gag gat gct	2305		
	Leu Leu Ile Arg Leu Tyr Gln Ala Leu Glu Ala Ile Gly Glu Asp Ala			
	65	70	75	80
45	cga aac gag ctt gat caa gag att cgc cag gat gaa gaa cta cga gtc	2353		
	Arg Asn Glu Leu Asp Gln Glu Ile Arg Gln Asp Glu Glu Leu Arg Val			
	85	90	95	
50	cgc ctt ttt gca ttg ttg ggt ggt tcc tct gct gtc ggt gat cac ttg	2401		
	Arg Leu Phe Ala Leu Leu Gly Gly Ser Ser Ala Val Gly Asp His Leu			
	100	105	110	
	gtc gcc aat cct ttg cag tgg aaa ctc tta aaa ctt gat gcg cca tct	2449		
55	Val Ala Asn Pro Leu Gln Trp Lys Leu Leu Lys Leu Asp Ala Pro Ser			
	115	120	125	

EP 1 229 121 A2

	agg gaa gag atg ttt cag gcg ctg ctg gaa tct gtg aaa gct cag cct	2497
	Arg Glu Glu Met Phe Gln Ala Leu Leu Glu Ser Val Lys Ala Gln Pro	
5	130 135 140	
	gct gtg ctt gag gtt gag gat ttc agc gat gca cac aac att gcc cga	2545
	Ala Val Leu Glu Val Glu Asp Phe Ser Asp Ala His Asn Ile Ala Arg	
	145 150 155 160	
10	gac gat ttg agc acg cct ggt ttt tac acg gct agt gtt acc ggg cct	2593
	Asp Asp Leu Ser Thr Pro Gly Phe Tyr Thr Ala Ser Val Thr Gly Pro	
	165 170 175	
15	gaa gca gag cga gtc ttg aaa tgg act tat cgc acg ttg ctg acc cgg	2641
	Glu Ala Glu Arg Val Leu Lys Trp Thr Tyr Arg Thr Leu Leu Thr Arg	
	180 185 190	
	att gct gcg cat gat tta gcg ggt acc tat ccc acc gac atg cgg aga	2689
20	Ile Ala Ala His Asp Leu Ala Gly Thr Tyr Pro Thr Asp Met Arg Arg	
	195 200 205	
	aaa ggt ggc gat cct gtt ccg ttt agc aca gtg acc atg cag ctg agc	2737
	Lys Gly Gly Asp Pro Val Pro Phe Ser Thr Val Thr Met Gln Leu Ser	
25	210 215 220	
	gac cta gct gat gct gct ttg act gct gct tta gct gtg gca att gcc	2785
	Asp Leu Ala Asp Ala Ala Leu Thr Ala Ala Leu Ala Val Ala Ile Ala	
	225 230 235 240	
30	aat gtt tat ggt gaa aag ccg gtt gat tca gct tta tct gtc atc gcg	2833
	Asn Val Tyr Gly Glu Lys Pro Val Asp Ser Ala Leu Ser Val Ile Ala	
	245 250 255	
35	atg ggc aaa tgt ggc gcg cag gaa ttg aac tac att tca gat gtg gac	2881
	Met Gly Lys Cys Gly Ala Gln Glu Leu Asn Tyr Ile Ser Asp Val Asp	
	260 265 270	
	gtg gtg ttt gtt gca gag ccg gca aac tct aaa tca aca cgc acc gca	2929
40	Val Val Phe Val Ala Glu Pro Ala Asn Ser Lys Ser Thr Arg Thr Ala	
	275 280 285	
	gca gag ctg att cgc atc ggt agc aac tgg ttc ttt gag gtg gat gca	2977
	Ala Glu Leu Ile Arg Ile Gly Ser Asn Ser Phe Phe Glu Val Asp Ala	
45	290 295 300	
	gca ctt cgc cca gaa ggt aaa agt ggc gct ctt gtg cgc tct ttg gat	3025
	Ala Leu Arg Pro Glu Gly Lys Ser Gly Ala Leu Val Arg Ser Leu Asp	
	305 310 315 320	
50	tcc cat atg gcg tat tac aag cgc tgg gcg gaa acc tgg gaa ttt cag	3073
	Ser His Met Ala Tyr Tyr Lys Arg Trp Ala Glu Thr Trp Glu Phe Gln	
	325 330 335	
55	gca ctg ctg aaa gct cgt ccc atg acg ggt gat att gac ctt ggg cag	3121
	Ala Leu Leu Lys Ala Arg Pro Met Thr Gly Asp Ile Asp Leu Gly Gln	

EP 1 229 121 A2

	340	345	350	
5	tcc tat gtg gat gct ctt tca ccg ttg att tgg gcg gct agc cag cgg			3169
	Ser Tyr Val Asp Ala Leu Ser Pro Leu Ile Trp Ala Ala Ser Gln Arg			
	355	360	365	
10	gaa tca ttt gtc aca gat gtc caa gct atg cgc cgt cga gtg ttg gac			3217
	Glu Ser Phe Val Thr Asp Val Gln Ala Met Arg Arg Arg Val Leu Asp			
	370	375	380	
	aat gtt ccg gaa gac ttg cgt gat cgt gag ctg aag ctt ggt cgc ggt			3265
	Asn Val Pro Glu Asp Leu Arg Asp Arg Glu Leu Lys Leu Gly Arg Gly			
15	385	390	395	400
	ggt ttg agg gat gtg gag ttt gct gtc cag ctg ctt cag atg gtg cat			3313
	Gly Leu Arg Asp Val Glu Phe Ala Val Gln Leu Leu Gln Met Val His			
	405	410	415	
20	ggt cgc att gat gag acg ttg cgg gtt cgg tca acg gta aat gct ttg			3361
	Gly Arg Ile Asp Glu Thr Leu Arg Val Arg Ser Thr Val Asn Ala Leu			
	420	425	430	
25	cat gtg ttg gtt gat cag gga tat gtg ggt cgt gaa gac ggg cat aat			3409
	His Val Leu Val Asp Gln Gly Tyr Val Gly Arg Glu Asp Gly His Asn			
	435	440	445	
	ctc att gag tgc tat gag ttt ttg cgc ctg ttg gag cat cgc ctt caa			3457
	Leu Ile Glu Ser Tyr Glu Phe Leu Arg Leu Leu Glu His Arg Leu Gln			
30	450	455	460	
	ttg gag cgg atc aag cgc act cac ttg tta ccg aaa cct gat gac cga			3505
	Leu Glu Arg Ile Lys Arg Thr His Leu Leu Pro Lys Pro Asp Asp Arg			
	465	470	475	480
35	atg aat atg cgc tgg ttg gcg cgc gct tct ggg ttt act ggt tgc atg			3553
	Met Asn Met Arg Trp Leu Ala Arg Ala Ser Gly Phe Thr Gly Ser Met			
	485	490	495	
40	gag caa agt tgc gcc aaa gct atg gaa cgg cat ttg cgt aag gtt cgt			3601
	Glu Gln Ser Ser Ala Lys Ala Met Glu Arg His Leu Arg Lys Val Arg			
	500	505	510	
45	ttg cag att cag tgc ttg cat agt cag ctg ttt tat cgg cca ctg ctg			3649
	Leu Gln Ile Gln Ser Leu His Ser Gln Leu Phe Tyr Arg Pro Leu Leu			
	515	520	525	
	aac tct gtg gtc aac ttg agc gcg gat gcc atc aga ttg tct ccg gat			3697
	Asn Ser Val Val Asn Leu Ser Ala Asp Ala Ile Arg Leu Ser Pro Asp			
50	530	535	540	
	gct gca aag cta caa ttg ggg gca ttg gga tac ctg cat cca tca cgt			3745
	Ala Ala Lys Leu Gln Leu Gly Ala Leu Gly Tyr Leu His Pro Ser Arg			
	545	550	555	560
55	gct tat gaa cac ctg act gct ctt gca tca gga gct agc cgt aaa gcc			3793

EP 1 229 121 A2

	Ala Tyr Glu His Leu Thr Ala Leu Ala Ser Gly Ala Ser Arg Lys Ala	
	565 570 575	
5	aag att cag gcg atg ttg ctg ccc acg ttg atg gag tgg ctg tct caa	3841
	Lys Ile Gln Ala Met Leu Leu Pro Thr Leu Met Glu Trp Leu Ser Gln	
	580 585 590	
10	aca gct gaa cca gat gcg gga ttg ctg aat tac cgc aag ctt tct gat	3889
	Thr Ala Glu Pro Asp Ala Gly Leu Leu Asn Tyr Arg Lys Leu Ser Asp	
	595 600 605	
15	gct tcc tat gat cgc agc tgg ttt ttg cgc atg ctg cgt gat gag ggc	3937
	Ala Ser Tyr Asp Arg Ser Trp Phe Leu Arg Met Leu Arg Asp Glu Gly	
	610 615 620	
20	gta gtg ggg cag cgg ttg atg cgt att ttg gga aat tct ccc tat att	3985
	Val Val Gly Gln Arg Leu Met Arg Ile Leu Gly Asn Ser Pro Tyr Ile	
	625 630 635 640	
25	tct gaa ctg att atc tcc act ccg gac ttt gtg aaa cag ctg ggt gat	4033
	Ser Glu Leu Ile Ile Ser Thr Pro Asp Phe Val Lys Gln Leu Gly Asp	
	645 650 655	
30	gcg gcg tct ggt cct aaa ttg ctt gct act gca ccg act cag gtt gtg	4081
	Ala Ala Ser Gly Pro Lys Leu Leu Ala Thr Ala Pro Thr Gln Val Val	
	660 665 670	
35	aaa gca atc aag gcg acg gtg tgc cgt cat gag tca cct gat cgg gcg	4129
	Lys Ala Ile Lys Ala Thr Val Ser Arg His Glu Ser Pro Asp Arg Ala	
	675 680 685	
40	atc cag gct gca cga tgc ctg agg agg cag gag ctg gca cgc att gcc	4177
	Ile Gln Ala Ala Arg Ser Leu Arg Arg Gln Glu Leu Ala Arg Ile Ala	
	690 695 700	
45	tct gct gat ttg ctg aac atg ctg act gtt cag gaa gta tgc caa agc	4225
	Ser Ala Asp Leu Leu Asn Met Leu Thr Val Gln Glu Val Cys Gln Ser	
	705 710 715 720	
50	ttg tca cta gtc tgg gat gcg gtg ttg gat gct gcc ttg gat gcg gaa	4273
	Leu Ser Leu Val Trp Asp Ala Val Leu Asp Ala Ala Leu Asp Ala Glu	
	725 730 735	
55	atc cgt gct gca ctt aac gat cca cag aaa cca gat cag cct ctg gcc	4321
	Ile Arg Ala Ala Leu Asn Asp Pro Gln Lys Pro Asp Gln Pro Leu Ala	
	740 745 750	
60	aat att tct gtg atc ggc atg ggc cgt ttg ggt gga gca gaa ctt gga	4369
	Asn Ile Ser Val Ile Gly Met Gly Arg Leu Gly Gly Ala Glu Leu Gly	
	755 760 765	
65	tac ggt tct gat gcc gat gtg atg ttt gla tgc gag ccg gla gcc ggt	4417
	Tyr Gly Ser Asp Ala Asp Val Met Phe Val Cys Glu Pro Val Ala Gly	
	770 775 780	

	gig gaa gag cat gag gcc glc aca tgg tct att gcg atc tgt gat tcc	4465
	Val Glu Glu His Glu Ala Val Thr Trp Ser Ile Ala Ile Cys Asp Ser	
5	785 790 795 800	
	alg cgg tgg agg ctt gcg cag cct tcc ggt gat cca cct ttg gag gig	4513
	Met Arg Ser Arg Leu Ala Gln Pro Ser Gly Asp Pro Pro Leu Glu Val	
	805 810 815	
10	gat ctg ggg ctg cgt cct gaa ggg aga tct ggt gcg att gig cgc acc	4561
	Asp Leu Gly Leu Arg Pro Glu Gly Arg Ser Gly Ala Ile Val Arg Thr	
	820 825 830	
15	glt gat tcc tat gig aag tac tac gaa aag tgg ggt gaa act tgg gag	4609
	Val Asp Ser Tyr Val Lys Tyr Tyr Glu Lys Trp Gly Glu Thr Trp Glu	
	835 840 845	
	att cag gcg ctg ctg agg gct gcg tgg gtt gct ggt gat cgt gag ctg	4657
20	Ile Gln Ala Leu Leu Arg Ala Ala Trp Val Ala Gly Asp Arg Glu Leu	
	850 855 860	
	ggc att aag ttc ttg gag tgg att gat cgt ttc cgc tac cca gtt gac	4705
	Gly Ile Lys Phe Leu Glu Ser Ile Asp Arg Phe Arg Tyr Pro Val Asp	
25	865 870 875 880	
	ggg gca acg cag gcg cag ctt cgt gaa gtt cgt cga att aag gcg agg	4753
	Gly Ala Thr Gln Ala Gln Leu Arg Glu Val Arg Arg Ile Lys Ala Arg	
	885 890 895	
30	gtg gat aat gag agg ctt ccg cgc ggg gct gat cga aat acc cat acc	4801
	Val Asp Asn Glu Arg Leu Pro Arg Gly Ala Asp Arg Asn Thr His Thr	
	900 905 910	
	aag ctg ggt cgg gga gcg tta act gac atc gag tgg act gtg cag ttg	4849
35	Lys Leu Gly Arg Gly Ala Leu Thr Asp Ile Glu Trp Thr Val Gln Leu	
	915 920 925	
	ttg acc alg alg cat gct cat gag att ccg gag ctg cac aat acg tgg	4897
	Leu Thr Met Met His Ala His Glu Ile Pro Glu Leu His Asn Thr Ser	
40	930 935 940	
	acg ttg gaa gtt ctt gaa gtg ctg gaa aag cat cag att att aac cct	4945
	Thr Leu Glu Val Leu Glu Val Leu Glu Lys His Gln Ile Ile Asn Pro	
45	945 950 955 960	
	gtg cag gtg cag acg ctt cgg gaa gcg tgg ctg acg gca acg gct gct	4993
	Val Gln Val Gln Thr Leu Arg Glu Ala Trp Leu Thr Ala Thr Ala Ala	
	965 970 975	
50	agg aat gcg ctt gtg ctg glc agg ggt aag aga tta gat cag tta cct	5041
	Arg Asn Ala Leu Val Leu Val Arg Gly Lys Arg Leu Asp Gln Leu Pro	
	980 985 990	
55	act cct ggt ccg cac ctt gcg cag gtg gct ggt gcg tct ggt tgg gat	5089
	Thr Pro Gly Pro His Leu Ala Gln Val Ala Gly Ala Ser Gly Trp Asp	

EP 1 229 121 A2

	995	1000	1005	
	cca aat gag tac cag gag tat ttg gaa aac tat ctg aaa gtg acc agg			5137
5	Pro Asn Glu Tyr Gln Glu Tyr Leu Glu Asn Tyr Leu Lys Val Thr Arg			
	1010	1015	1020	
	aag agt cgt cag gtt gtt gat gaa gtc ttc tgg ggt gtg gac tct atg			5185
	Lys Ser Arg Gln Val Val Asp Glu Val Phe Trp Gly Val Asp Ser Met			
10	1025	1030	1035	1040
	gag caa cgt gag ttt taggtagggt ggggagccc caaagttgcg gaaaatgtt c			5241
	Glu Gln Arg Glu Phe			
	1045			
15	caactaaggg actatagtta gggtgggata acctaaagttat atctttttgtg agcgtgagga			5301
	tttctctgag gaatctagac gcagattaac ttccgcttgg cagcgaccgg gataacaccg			5361
	cggttgcggc cagcaggct cacaaggac accactatga caagcattat tgcaagcaac			5421
20	agcgacctat cggaggagct gcgcacccac actgcgcggg cacatgaaga ggccgagcac			5481
	tcaacgttta tgaatgac			5500
	<210> 2			
25	<211> 446			
	<212> PRT			
	<213> Brevibacterium lactofermentum			
	<400> 2			
30	Met Asn Ser Glu Gln Glu Phe Val Leu Ser Ala Ile Glu Glu Arg Asp			
	1 5 10 15			
	Ile Lys Phe Val Arg Leu Trp Phe Thr Asp Ile Leu Gly His Leu Lys			
35	20 25 30			
	Ser Val Val Val Ala Pro Ala Glu Leu Glu Ser Ala Leu Glu Glu Gly			
	35 40 45			
40	Ile Gly Phe Asp Gly Ser Ala Ile Glu Gly Tyr Ala Arg Ile Ser Glu			
	50 55 60			
	Ala Asp Thr Ile Ala Arg Pro Asp Pro Ser Thr Phe Gln Val Leu Pro			
	65 70 75 80			
45	Leu Glu Ala Gly Ile Ser Lys Leu Gln Ala Ala Arg Leu Phe Cys Asp			
	85 90 95			
	Val Thr Met Pro Asp Gly Gln Pro Ser Phe Ser Asp Pro Arg Gln Val			
	100 105 110			
50	Leu Arg Arg Gln Val Gln Leu Ala Ala Asp Glu Gly Leu Thr Cys Met			
	115 120 125			
	Ile Ser Pro Glu Ile Glu Phe Tyr Leu Val Gln Ser Leu Arg Thr Asn			
	130 135 140			
55	Gly Leu Pro Pro Val Pro Thr Asp Asn Gly Gly Tyr Phe Asp Gln Ala			

EP 1 229 121 A2

	145	150	155	160
	Thr Phe Asn Glu Ala	Pro Asn Phe Arg Arg	Asn Ala Met Val	Ala Leu
5		165	170	175
	Glu Glu Leu Gly Ile	Pro Val Glu Phe Ser His His	Glu Thr Ala Pro	
		180	185	190
	Gly Gln Gln Glu Ile	Asp Leu Arg His Ala Asp	Ala Leu Thr Met	Ala
10		195	200	205
	Asp Asn Ile Met Thr	Phe Arg Tyr Ile Met Lys	Gln Val Ala Arg	Asp
		210	215	220
	Gln Gly Val Gly Ala	Ser Phe Met Pro Lys Pro	Phe Gln Glu His	Ala
15		225	230	235
		240	245	250
	Gly Ser Ala Met His	Thr His Met Ser Leu Phe	Glu Gly Asp Thr	Asn
		255	260	265
	Ala Phe His Asp Pro	Asp Asp Ser Tyr Met Leu	Ser Lys Thr Ala	Lys
20		270	275	280
	Gln Phe Ile Ala Gly	Ile Leu His His Ala Pro	Glu Phe Thr Ala	Val
		285	290	295
	Thr Asn Gln Trp Val	Asn Ser Tyr Lys Arg Ile	Val Tyr Gly Asn	Glu
25		300	305	310
	Ala Pro Thr Ala Ala	Thr Trp Gly Val Ser Asn	Arg Ser Ala Leu	Val
		315	320	325
	Arg Val Pro Thr Tyr	Arg Leu Asn Lys Glu Glu	Ser Arg Arg Val	Glu
30		330	335	340
	Val Arg Leu Pro Asp	Thr Ala Cys Asn Pro Tyr	Leu Ala Phe Ser	Val
		345	350	355
	Met Leu Gly Ala Gly	Leu Lys Gly Ile Lys Glu	Gly Tyr Glu Leu	Asp
35		360	365	370
	Glu Pro Ala Glu Asp	Asp Ile Ser Asn Leu Ser	Phe Arg Glu Arg	Arg
		375	380	385
	Ala Met Gly Tyr Asn	Asp Leu Pro Asn Ser Leu	Asp Gln Ala Leu	Arg
40		390	395	400
	Gln Met Glu Lys Ser	Glu Leu Val Ala Asp Ile	Leu Gly Glu His	Val
		405	410	415
	Phe Glu Phe Phe Leu	Arg Asn Lys Trp Arg Glu	Trp Arg Asp Tyr	Gln
45		420	425	430
	Glu Gln Ile Thr Pro	Trp Glu Leu Arg Asn	Asn Leu Asp Tyr	
50		435	440	445

<210> 3

<211> 1045

<212> PRT

<213> Brevibacterium lactofermentum

5 <400> 3
 Met Ser Gly Pro Leu Arg Ser Glu Arg Lys Val Val Gly Phe Val Arg
 1 5 10 15
 Asp Pro Leu Pro Lys Val Gly Ser Leu Ser Leu Lys Ser Glu His Ala
 10 20 25 30
 Gln Ala Asp Leu Glu His Leu Gly Trp Arg Asn Val Glu Ser Leu Asp
 35 40 45
 Leu Leu Trp Gly Leu Ser Gly Ala Gly Asp Pro Asp Val Ala Leu Asn
 15 50 55 60
 Leu Leu Ile Arg Leu Tyr Gln Ala Leu Glu Ala Ile Gly Glu Asp Ala
 65 70 75 80
 Arg Asn Glu Leu Asp Gln Glu Ile Arg Gln Asp Glu Glu Leu Arg Val
 20 85 90 95
 Arg Leu Phe Ala Leu Leu Gly Gly Ser Ser Ala Val Gly Asp His Leu
 100 105 110
 Val Ala Asn Pro Leu Gln Trp Lys Leu Leu Lys Leu Asp Ala Pro Ser
 25 115 120 125
 Arg Glu Glu Met Phe Gln Ala Leu Leu Glu Ser Val Lys Ala Gln Pro
 130 135 140
 Ala Val Leu Glu Val Glu Asp Phe Ser Asp Ala His Asn Ile Ala Arg
 30 145 150 155 160
 Asp Asp Leu Ser Thr Pro Gly Phe Tyr Thr Ala Ser Val Thr Gly Pro
 165 170 175
 Glu Ala Glu Arg Val Leu Lys Trp Thr Tyr Arg Thr Leu Leu Thr Arg
 35 180 185 190
 Ile Ala Ala His Asp Leu Ala Gly Thr Tyr Pro Thr Asp Met Arg Arg
 195 200 205
 Lys Gly Gly Asp Pro Val Pro Phe Ser Thr Val Thr Met Gln Leu Ser
 40 210 215 220
 Asp Leu Ala Asp Ala Ala Leu Thr Ala Ala Leu Ala Val Ala Ile Ala
 225 230 235 240
 Asn Val Tyr Gly Glu Lys Pro Val Asp Ser Ala Leu Ser Val Ile Ala
 245 250 255
 Met Gly Lys Cys Gly Ala Gln Glu Leu Asn Tyr Ile Ser Asp Val Asp
 50 260 265 270
 Val Val Phe Val Ala Glu Pro Ala Asn Ser Lys Ser Thr Arg Thr Ala
 275 280 285
 Ala Glu Leu Ile Arg Ile Gly Ser Asn Ser Phe Phe Glu Val Asp Ala
 55 290 295 300

	Ala Leu Arg Pro Glu Gly Lys Ser Gly Ala Leu Val Arg Ser Leu Asp	
	305	310 315 320
5	Ser His Met Ala Tyr Tyr Lys Arg Trp Ala Glu Thr Trp Glu Phe Gln	
		325 330 335
	Ala Leu Leu Lys Ala Arg Pro Met Thr Gly Asp Ile Asp Leu Gly Gln	
		340 345 350
10	Ser Tyr Val Asp Ala Leu Ser Pro Leu Ile Trp Ala Ala Ser Gln Arg	
		355 360 365
	Glu Ser Phe Val Thr Asp Val Gln Ala Met Arg Arg Arg Val Leu Asp	
		370 375 380
15	Asn Val Pro Glu Asp Leu Arg Asp Arg Glu Leu Lys Leu Gly Arg Gly	
		385 390 395 400
	Gly Leu Arg Asp Val Glu Phe Ala Val Gln Leu Leu Gln Met Val His	
		405 410 415
20	Gly Arg Ile Asp Glu Thr Leu Arg Val Arg Ser Thr Val Asn Ala Leu	
		420 425 430
	His Val Leu Val Asp Gln Gly Tyr Val Gly Arg Glu Asp Gly His Asn	
		435 440 445
25	Leu Ile Glu Ser Tyr Glu Phe Leu Arg Leu Leu Glu His Arg Leu Gln	
		450 455 460
	Leu Glu Arg Ile Lys Arg Thr His Leu Leu Pro Lys Pro Asp Asp Arg	
		465 470 475 480
30	Met Asn Met Arg Trp Leu Ala Arg Ala Ser Gly Phe Thr Gly Ser Met	
		485 490 495
	Glu Gln Ser Ser Ala Lys Ala Met Glu Arg His Leu Arg Lys Val Arg	
		500 505 510
35	Leu Gln Ile Gln Ser Leu His Ser Gln Leu Phe Tyr Arg Pro Leu Leu	
		515 520 525
	Asn Ser Val Val Asn Leu Ser Ala Asp Ala Ile Arg Leu Ser Pro Asp	
		530 535 540
40	Ala Ala Lys Leu Gln Leu Gly Ala Leu Gly Tyr Leu His Pro Ser Arg	
		545 550 555 560
	Ala Tyr Glu His Leu Thr Ala Leu Ala Ser Gly Ala Ser Arg Lys Ala	
		565 570 575
45	Lys Ile Gln Ala Met Leu Leu Pro Thr Leu Met Glu Trp Leu Ser Gln	
		580 585 590
50	Thr Ala Glu Pro Asp Ala Gly Leu Leu Asn Tyr Arg Lys Leu Ser Asp	
		595 600 605
	Ala Ser Tyr Asp Arg Ser Trp Phe Leu Arg Met Leu Arg Asp Glu Gly	
		610 615 620
55	Val Val Gly Gln Arg Leu Met Arg Ile Leu Gly Asn Ser Pro Tyr Ile	

EP 1 229 121 A2

	625	630	635	640
	Ser	Glu	Leu	Ile
5		645	650	655
	Ala	Ala	Ser	Gly
		660	665	670
	Lys	Ala	Ile	Lys
10		675	680	685
	Ile	Gln	Ala	Ala
		690	695	700
	Ser	Ala	Asp	Leu
15		705	710	715
	Leu	Ser	Leu	Val
		725	730	735
	Ile	Arg	Ala	Ala
20		740	745	750
	Asn	Ile	Ser	Val
		755	760	765
	Tyr	Gly	Ser	Asp
25		770	775	780
	Val	Glu	Glu	His
		785	790	795
	Met	Arg	Ser	Arg
30		805	810	815
	Asp	Leu	Gly	Leu
		820	825	830
	Val	Asp	Ser	Tyr
35		835	840	845
	Ile	Gln	Ala	Leu
		850	855	860
	Gly	Ile	Lys	Phe
40		865	870	875
	Gly	Ala	Thr	Gln
		885	890	895
	Val	Asp	Asn	Glu
45		900	905	910
	Lys	Leu	Gly	Arg
		915	920	925
	Leu	Thr	Met	Met
50		930	935	940
	Thr	Leu	Glu	Val
55		945	950	955
				960

EP 1 229 121 A2

Val Gln Val Gln Thr Leu Arg Glu Ala Trp Leu Thr Ala Thr Ala Ala
 965 970 975
 5 Arg Asn Ala Leu Val Leu Val Arg Gly Lys Arg Leu Asp Gln Leu Pro
 980 985 990
 Thr Pro Gly Pro His Leu Ala Gln Val Ala Gly Ala Ser Gly Trp Asp
 995 1000 1005
 10 Pro Asn Glu Tyr Gln Glu Tyr Leu Glu Asn Tyr Leu Lys Val Thr Arg
 1010 1015 1020
 Lys Ser Arg Gln Val Val Asp Glu Val Phe Trp Gly Val Asp Ser Met
 1025 1030 1035 1040
 15 Glu Gln Arg Glu Phe
 1045

20 <210> 4
 <211> 29
 <212> DNA
 <213> Artificial/Unknown

25 <220>
 <221> misc_feature
 <222> 0..0
 30 <223> Description of Artificial Sequence: primer

<400> 4
 ggggtcgacg gatcgacagg taatgcatt 29

35 <210> 5
 <211> 29
 <212> DNA
 40 <213> Artificial/Unknown

<220>
 45 <221> misc_feature
 <222> 0..0
 <223> Description of Artificial Sequence: primer

50 <400> 5
 ggggtcgacg gatccaccat gatggagga 29

55 <210> 6
 <211> 22

5 <212> DNA
 <213> Artificial/Unknown

 <220>
 <221> misc_feature
 <222> 0..0
 10 <223> Description of Artificial Sequence: primer

 <400> 6
 cttcccagta gcaccatagc ac 22
 15

 <210> 7
 <211> 26
 <212> DNA
 20 <213> Artificial/Unknown

 <220>
 <221> misc_feature
 25 <222> 0..0
 <223> Description of Artificial Sequence: primer

 <400> 7
 ctggtggcag ttcgaagagg tccttg 26
 30

 <210> 8
 35 <211> 26
 <212> DNA
 <213> Artificial/Unknown

 <220>
 <221> misc_feature
 <222> 0..0
 40 <223> Description of Artificial Sequence: primer
 45

 <400> 8
 ggacaaggac ctcttcgaac tgccag 26
 50

 <210> 9
 <211> 26
 <212> DNA
 55 <213> Artificial/Unknown

5 <220>
 <221> misc_feature
 <222> 0..0
 <223> Description of Artificial Sequence: primer

10 <400> 9
 cggcgagacc gtcgattggg aggagc 26

15 <210> 10
 <211> 22
 <212> DNA
 <213> Artificial/Unknown

20 <220>
 <221> misc_feature
 <222> 0..0
25 <223> Description of Artificial Sequence: primer

 <400> 10
 gtagcacctt acgaccaaac cg 22

30 <210> 11
 <211> 20
 <212> DNA
35 <213> Artificial/Unknown

 <220>
 <221> misc_feature
40 <222> 0..0
 <223> Description of Artificial Sequence: primer

45 <400> 11
 ggagccggtc gacgaggagc 20

50 <210> 12
 <211> 25
 <212> DNA
 <213> Artificial/Unknown

55 <220>

<223> Description of Artificial Sequence: primer

5 <400> 15
 cillccccaga ctcigccc 18

10	$\langle 210 \rangle$	16
	$\langle 211 \rangle$	22
	$\langle 212 \rangle$	DNA
	$\langle 213 \rangle$	Artificial/Unknown

```

15      <220>
      <221> misc_feature
      <222> 0..0
20      <223> Description of Artificial Sequence: primer

```

<400> 16
cgctgcata atgaacgtg ag 22

	$\langle 210 \rangle$	17
	$\langle 211 \rangle$	44
	$\langle 212 \rangle$	DNA
30	$\langle 213 \rangle$	Artificial/Unknown

```

35      <220>
      <221> misc_feature
      <222> 0..0
      <223> Description of Artificial Sequence: primer

```

40 <400> 17
 cittgttgcc atactgtgc gacgtgtc laattgaacg tgag 44

	$\langle 210 \rangle$	18
	$\langle 211 \rangle$	21
45	$\langle 212 \rangle$	DNA
	$\langle 213 \rangle$	Artificial/Unknown

```

50      <220>
      <221> misc_feature
      <222> 0..0
      <223> Description of Artificial Sequence: primer

```

5 <400> 18
 ccaccacgaa gtcgglggcg g 23

10 <210> 19
 <211> 21
 <212> DNA
 <213> Artificial/Unknown

15 <220>
 <221> misc_feature
 <222> 0..0
 <223> Description of Artificial Sequence: primer

20 <400> 19
 ttggagcctc gaagccigga a 21

25 <210> 20
 <211> 29
 <212> DNA
 <213> Brevibacterium flavum

30 <400> 20
 tggtcataac tgtgcgacgc tgccataat 29

35 <210> 21
 <211> 29
 <212> DNA
 <213> Artificial/Unknown

40 <220>
 <221> misc_feature
 <222> 0..0
 <223> Description of Artificial Sequence: sequence of

45 promoter

50 <400> 21
 tggtcataac tgtgcgacgc tgctataat 29

55 <210> 22
 <211> 29
 <212> DNA

5 <213> Artificial/Unknown
 <220>
 <221> misc_feature
 <222> 0..0
 10 <223> Description of Artificial Sequence: sequence of
 promoter

 <400> 22
 15 llgccatalc tlgcgacgc tgcataat 29

 <210> 23
 <211> 23
 20 <212> DNA
 <213> Artificial/Unknown

 <220>
 25 <221> misc_feature
 <222> 0..0
 <223> Description of Artificial Sequence: primer

 30 <400> 23
 agacctacga glccgccttt llg 23

 <210> 24
 35 <211> 21
 <212> DNA
 <213> Artificial/Unknown

 40 <220>
 <221> misc_feature
 <222> 0..0
 45 <223> Description of Artificial Sequence: primer

 <400> 24
 50 cgalcaccag caaccacgc a 21

 55

Claims

1. A coryneform bacterium which has L-glutamine producing ability and has been modified so that its intracellular glutamine synthetase activity should be enhanced.
2. The bacterium according to Claim 1, wherein the glutamine synthetase activity is enhanced by increasing expression amount of a glutamine synthetase gene.
3. The bacterium according to Claim 2, wherein the expression amount of the glutamine synthetase gene is increased by increasing copy number of a gene coding for glutamine synthetase or modifying an expression control sequence of the gene so that expression of the gene coding for the intracellular glutamine synthetase of the bacterium should be enhanced.
4. The bacterium according to Claim 1, wherein the glutamine synthetase activity is enhanced by deficiency in activity control of intracellular glutamine synthetase by adenylation.
5. The bacterium according to Claim 4, wherein the activity control of intracellular glutamine synthetase by adenylation is defected by one or more of harboring glutamine synthetase of which activity control by adenylation is defected, decrease of glutamine synthetase adenylyl transferase activities in the bacterial cell and decrease of PII protein activity in the bacterial cell.
6. The bacterium according to any one of Claims 1-5, wherein the bacterium has been further modified so that its intracellular glutamate dehydrogenase activity should be enhanced.
7. The bacterium according to Claim 6, wherein the glutamate dehydrogenase activity is enhanced by increasing expression amount of a glutamate dehydrogenase gene.
8. The bacterium according to Claim 7, wherein the expression amount of the glutamate dehydrogenase gene is increased by increasing copy number of the gene coding for glutamate dehydrogenase or modifying an expression control sequence of the gene so that expression of the gene coding for the intracellular glutamate dehydrogenase of the bacterium should be increased.
9. A method for producing L-glutamine, which comprises culturing a bacterium according to any one of Claims 1-8 in a medium to produce and accumulate L-glutamine in the medium and collecting the L-glutamine.
10. A DNA coding for a protein defined in the following (A) or (B):
 - (A) a protein that has the amino acid sequence of SEQ ID NO: 2,
 - (B) a protein that has the amino acid sequence of SEQ ID NO: 2 including substitution, deletion, insertion, addition or inversion of one or several amino acid residues and has glutamine synthetase activity.
11. The DNA according to Claim 10, which is a DNA defined in the following (a) or (b):
 - (a) a DNA containing the nucleotide sequence of the nucleotide numbers 659-1996 in the nucleotide sequence of SEQ ID NO: 1,
 - (b) a DNA that is hybridizable with the nucleotide sequence of the nucleotide numbers 659-1996 in the nucleotide sequence of SEQ ID NO: 1 or a probe that can be prepared from the sequence under the stringent conditions and codes for a protein having glutamine synthetase activity.
12. A DNA coding for a protein defined in the following (C) or (D):
 - (C) a protein that has the amino acid sequence of SEQ ID NO: 3,
 - (D) a protein that has the amino acid sequence of SEQ ID NO: 3 including substitution, deletion, insertion, addition or inversion of one or several amino acid residues and has glutamine synthetase adenylyl transferase activities.
13. The DNA according to Claim 12, which is a DNA defined in the following (c) or (d):

EP 1 229 121 A2

(c) a DNA containing the nucleotide sequence of nucleotide numbers 2006-5200 in the nucleotide sequence of SEQ ID NO: 1,

(d) a DNA that is hybridizable with the nucleotide sequence of the nucleotide numbers 2006-5200 in the nucleotide sequence of SEQ ID NO: 1 or a probe that can be prepared from the sequence under the stringent conditions and codes for a protein having glutamine synthetase adenylyl transferase activities.

5

10

15

20

25

30

35


40

45

50

55

This Page Blank (uspto)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 229 121 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
12.03.2003 Bulletin 2003/11

(51) Int Cl.7: **C12N 15/52**, C12N 9/00,
C12P 13/14, C12N 1/21
// C12R1/15

(43) Date of publication A2:
07.08.2002 Bulletin 2002/32

(21) Application number: **02001993.1**

(22) Date of filing: **05.02.2002**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **05.02.2001 JP 2001028163**
30.05.2001 JP 2001162806

(71) Applicant: **Ajinomoto Co., Inc.**
Tokyo 104 (JP)

(72) Inventors:
• **Nakamura, Jun, c/o Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)

- **Izui, Hiroshi, c/o Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)
- **Moriguchi, Kayo, c/o Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)
- **Kawashima, Hiroki, Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)
- **Nakamatsu, Tsuyoshi,**
c/o Tokyo Denki University
Tokyo (JP)
- **Kurahashi, Osamu, c/o Ajinomoto Co., Inc.**
Kawasaki-shi, Kanagawa (JP)

(74) Representative: **HOFFMANN - EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **Method for producing L-glutamine by fermentation and L-glutamine producing bacterium**

(57) L-Glutamine is produced by culturing a coryneform bacterium which has L-glutamine producing ability and has been modified so that its intracellular glutamine synthetase activity should be enhanced, preferably which has been further modified so that its intracellular

glutamate dehydrogenase activity should be enhanced, in a medium to produce and accumulate L-glutamine in the medium and collecting the L-glutamine.

EP 1 229 121 A3

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 1993

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (InCL7)
X	DATABASE EMBL [Online] 24 January 2001 (2001-01-24) "sequence 95 from patent W00100843" retrieved from EBI Database accession no. AX063813 XP002226627 -& WO 01 00843 A (BASF AG) 4 January 2001 (2001-01-04) ---	10,11	C12N15/52 C12N9/00 C12P13/14 C12N1/21 //C12R1/15
X	DATABASE EMBL [Online] 24 January 2001 (2001-01-24) "sequence 99 from patent W00100843" retrieved from EBI Database accession no. AX063817 XP002226628 -& WO 01 00843 A (BASF AG) 4 January 2001 (2001-01-04) ---	12,13	
X	US 3 886 039 A (YOSHINAGA FUMIHIRO ET AL) 27 May 1975 (1975-05-27) * abstract * * column 1, line 65 - line 66 * * column 2, line 1 - line 4 * * column 4; example 1 * * column 5; table 4 * ---	1-9	TECHNICAL FIELDS SEARCHED (InCL7) C12N C12P
D,X	BOERMANN ET AL: "Molecular analysis of the Corynebacterium glutamicum gdh gene encoding glutamate dehydrogenase" MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 6, no. 3, February 1992 (1992-02), pages 317-326, XP000864663 ISSN: 0950-382X * summary, first sentence * * page 317, right-hand column, reactions 1 and 2a * --- -/-	3,8	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 10 January 2003	Examiner Grötzinger, T
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EP 02 00 1993 A3 02 00 1993 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 00 1993

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	JAKOBY MARC ET AL: "Isolation of the <i>Corynebacterium glutamicum</i> glnA gene encoding glutamine synthetase I." FEMS MICROBIOLOGY LETTERS, vol. 154, no. 1, 1997, pages 81-88, XP002226625 ISSN: 0378-1097 * abstract *	3	
D,X	JAKOBY MARC ET AL: "Nitrogen regulation in <i>Corynebacterium glutamicum</i> : Isolation of genes involved and biochemical characterization of corresponding proteins." FEMS MICROBIOLOGY LETTERS, vol. 173, no. 2, 15 April 1999 (1999-04-15), pages 303-310, XP002226626 ISSN: 0378-1097 * abstract * * page 303, right-hand column * * page 305, results and discussion-section 3.1 *	5	
A	--- DATABASE EMBL [Online] 22 January 2001 (2001-01-22) "sequence 96 from patent W00100843" retrieved from EBI Database accession no. AX063814 XP002226629	10,11	
A	--- DATABASE EMBL [Online] 22 January 2001 (2001-01-22) "sequence 100 from patent W00100843" retrieved from EBI Database accession no. AX063818 XP002226630 -----	12,13	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 10 January 2003	Examiner Grötzinger, T
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPC FORM 1503 (03-02) (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 00 1993

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-01-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0100843 A	04-01-2001	AU 5421300 A	31-01-2001
		BR 0011806 A	14-05-2002
		CN 1371417 T	25-09-2002
		EP 1257649 A2	20-11-2002
		WO 0100843 A2	04-01-2001
		TR 200103707 T2	23-09-2002
		AU 5559000 A	31-01-2001
		BR 0011805 A	14-05-2002
		CN 1370235 T	18-09-2002
		EP 1263963 A2	11-12-2002
		WO 0100844 A2	04-01-2001
		TR 200103706 T2	21-10-2002
		AU 5836900 A	31-01-2001
		BR 0011811 A	18-06-2002
		WO 0100804 A2	04-01-2001
		SK 18882001 A3	10-09-2002
		TR 200103709 T2	21-08-2002
		AU 5421600 A	31-01-2001
		BR 0011810 A	07-05-2002
		CN 1370236 T	18-09-2002
		EP 1255839 A2	13-11-2002
		WO 0100805 A2	04-01-2001
		TR 200103708 T2	21-08-2002
		AU 5420500 A	31-01-2001
		BR 0011803 A	09-04-2002
		CN 1370234 T	18-09-2002
		EP 1254232 A2	06-11-2002
		ES 2176128 T1	01-12-2002
		WO 0100842 A2	04-01-2001
		SK 18902001 A3	10-09-2002
		TR 200103711 T2	22-07-2002
US 3886039 A	27-05-1975	JP 939649 C	30-01-1979
		JP 49081587 A	06-08-1974
		JP 53017675 B	09-06-1978
		DE 2362288 A1	20-06-1974
		FR 2210663 A1	12-07-1974
		GB 1428497 A	17-03-1976

EPO FORM P0455

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82